



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C07D 487/04, 471/04, C07F 9/32, C07K 14/81, A61K 31/47, 31/40, 31/66</b>		A1	(11) International Publication Number: <b>WO 98/11109</b>
			(43) International Publication Date: 19 March 1998 (19.03.98)
(21) International Application Number: <b>PCT/US97/16156</b>		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 12 September 1997 (12.09.97)			
(30) Priority Data: 60/026,011 12 September 1996 (12.09.96) US 08/710,621 20 September 1996 (20.09.96) US			
(71) Applicant: IDUN PHARMACEUTICALS, INCORPORATED [US/US]; Suite 300, 11085 North Torrey Pines Road, La Jolla, CA 92037 (US).			
(72) Inventors: KARANEWSKY, Donald, S.; 1797 Continental Lane, Escondido, CA 92024 (US). LINTON, Steven, D.; 11320 Red Cedar Drive, San Diego, CA 92131 (US).			
(74) Agent: STEINHARDT, Paul, C.; Campbell & Flores LLP, Suite 700, 4370 La Jolla Village Drive, San Diego, CA 92122 (US).		<b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(54) Title: NOVEL TRICYCLIC COMPOUNDS FOR THE INHIBITION OF THE ICE/CED-3 PROTEASE FAMILY OF ENZYMES			
(57) Abstract  This invention is directed to novel tricyclic ICE/ced-3 family inhibitor compounds. The invention is also directed to pharmaceutical compositions of such tricyclic compounds, plus the use of such compositions in the treatment of patients suffering inflammatory, autoimmune and neurodegenerative diseases, and for the prevention of ischemic injury.			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NI	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

NOVEL TRICYCLIC COMPOUNDS FOR THE INHIBITION  
OF THE ICE/CED-3 PROTEASE FAMILY OF ENZYMES

BACKGROUND OF THE INVENTION

The present invention relates to novel classes  
5 of compounds which are inhibitors of interleukin-1 $\beta$   
converting enzyme and related proteases ("ICE/ced-3  
family of cysteine proteases"). This invention also  
relates to pharmaceutical compositions comprising these  
compounds and to methods of using such pharmaceutical  
10 compositions. The compounds, pharmaceutical compositions  
and methods of this invention are particularly well  
suited for inhibiting the protease activity of the  
ICE/ced-3 family and consequently, may be advantageously  
used as agents against interleukin-1 ("IL-1") mediated  
15 diseases, including inflammatory diseases, autoimmune  
diseases and neurodegenerative diseases and for  
inhibiting unwanted apoptosis in various disease states  
such as ischemic injury to the heart (e.g., myocardial  
infarction), brain (e.g., stroke), and kidney (e.g.,  
20 ischemic kidney disease).

Interleukin 1 ("IL-1") is a major pro-  
inflammatory and immunoregulatory protein that stimulates  
fibroblast differentiation and proliferation, the  
production of prostaglandins, collagenase and  
25 phospholipase by synovial cells and chondrocytes,  
basophil and eosinophil degranulation and neutrophil  
activation. Oppenheim, J.H. et al., Immunology Today,  
7:45-56 (1986). As such, it is involved in the  
pathogenesis of chronic and acute inflammatory and  
30 autoimmune diseases. IL-1 is predominantly produced by  
peripheral blood monocytes as part of the inflammatory  
response. Mosely, B.S. et al., Proc. Nat. Acad. Sci.,

84:4572-4576 (1987); Lonnemann, G. et al., Eur. J. Immunol., 19:1531-1536 (1989).

IL-1 $\beta$  is synthesized as a biologically inactive precursor, proIL-1 $\beta$ . ProIL-1 $\beta$  is cleaved by a cysteine protease called interleukin-1 $\beta$  converting enzyme ("ICE") between Asp-116 and Ala-117 to produce the biologically active C-terminal fragment found in human serum and synovial fluid. Sleath, P.R. et al., J. Biol. Chem., 265:14526-14528 (1992); A.D. Howard et al., J. Immunol., 147:2964-2969 (1991).

ICE is a cysteine protease localized primarily in monocytes. In addition to promoting the pro-inflammatory and immunoregulatory properties of IL-1 $\beta$ , ICE, and particularly its homologues, also appear to be involved in the regulation of cell death or apoptosis. Yuan, J. et al., Cell, 75:641-652 (1993); Miura, M. et al., Cell, 75:653-660 (1993); Nett-Giordalisi, M.A. et al., J. Cell Biochem., 17B:117 (1993). In particular, ICE or ICE/ced-3 homologues are thought to be associated with the regulation of apoptosis in neurodegenerative diseases, such as Alzheimer's and Parkinson's disease. Marx, J. and M. Baringa, Science, 259:760-762 (1993); Gagliardini, V. et al., Science, 263:826-828 (1994).

Thus, disease states in which inhibitors of the ICE/ced-3 family of cysteine proteases may be useful as therapeutic agents include: infectious diseases, such as meningitis and salpingitis; septic shock, respiratory diseases; inflammatory conditions, such as arthritic cholangitis, colitis, encephalitis, endocervicitis and hepatitis, pancreatitis and reperfusion injury such as diseases such as the myocardial infarction, ischemic kidney disease; immune-based

hypersensitivity; auto-immune diseases, such as multiple sclerosis; bone diseases; and certain neurodegenerative diseases, such as Alzheimer's and Parkinson's disease.


ICE inhibitors represent a class of compounds useful for the control of the above-listed disease states. Peptide and peptidyl inhibitors of ICE have been described. However, such inhibitors have been typically characterized by undesirable pharmacologic properties, such as poor oral absorption, poor stability and rapid metabolism. Plattner, J.J. and D.W. Norbeck, in Drug  
10 Discovery Technologies, C.R. Clark and W.H. Moos, Eds. (Ellis Horwood, Chichester, England, 1990), pp. 92-126. These undesirable properties have hampered their development into effective drugs.

15 Accordingly, the need exists for compounds that can effectively inhibit the action of the ICE/ced-3 family of proteases, for use as agents for preventing unwanted apoptosis and for treating chronic and acute forms of IL-1 mediated diseases, such as inflammatory,  
20 autoimmune or neurodegenerative diseases.

The compounds of this invention incorporate a conformationally constrained dipeptide mimetic. This mimetic exhibits improved properties relative to their peptidic counterparts, for example, such as improved  
25 absorption and metabolic stability resulting in enhanced bioavailability.

SUMMARY OF THE INVENTION

One aspect of this invention is compounds of the formula:



FORMULA 1

wherein:


n is 1 or 2;

m is 1 or 2;

A is  $R^2CO-$ ,  $R^3-O-CO-$ , or  $R^4SO_2-$ ;

a group of the formula:

5



further wherein:

$\text{R}^1$  is a hydrogen atom, alkyl or phenylalkyl;

5  $\text{R}^2$  is alkyl, cycloalkyl, (cycloalkyl)alkyl, phenyl, phenylalkyl, substituted phenyl, (substituted phenyl)alkyl, heteroaryl, or (heteroaryl)alkyl;

10  $\text{R}^3$  is alkyl, cycloalkyl, (cycloalkyl)alkyl, phenylalkyl or (substituted phenyl)alkyl;

$\text{R}^4$  is alkyl, cycloalkyl, (cycloalkyl)alkyl, phenyl, phenylalkyl, substituted phenyl, (substituted phenyl)alkyl, heteroaryl, or (heteroaryl)alkyl;

15  $\text{R}^5$  is alkyl, cycloalkyl, (cycloalkyl)alkyl, phenyl, phenylalkyl, substituted phenyl, (substituted phenyl)alkyl, heteroaryl, or (heteroaryl)alkyl;

20  $\text{R}^6$  is alkyl, cycloalkyl, (cycloalkyl)alkyl, phenylalkyl, or (substituted phenyl)alkyl;


$\text{R}^7$  is alkyl, cycloalkyl, (cycloalkyl)alkyl, phenyl, phenylalkyl, substituted phenyl,

(substituted phenyl)alkyl, heteroaryl, or  
(heteroaryl)alkyl;

R<sup>8</sup> is an amino acid side chain chosen from  
the group consisting of natural and  
unnatural amino acids;


B is a hydrogen atom, a deuterium atom, alkyl,  
cycloalkyl, (cycloalkyl)alkyl, phenyl,  
phenylalkyl, substituted phenyl, (substituted  
phenyl)alkyl, heteroaryl, (heteroaryl)alkyl, or  
a halomethyl group;

a group of the formula:




wherein R<sup>9</sup> is phenyl, substituted phenyl,  
phenylalkyl, (substituted phenyl)alkyl,  
heteroaryl, or (heteroaryl)alkyl; and X is an  
oxygen or a sulfur atom;


a group of the formula:



a group of the formula:



a group of the formula:





wherein R<sup>10</sup> and R<sup>11</sup> are independently selected from a group consisting of alkyl, cycloalkyl, phenyl, substituted phenyl, phenylalkyl, and (substituted phenyl)alkyl;

5 or a pharmaceutically-acceptable salt thereof.

A further aspect of the instant invention are pharmaceutical compositions comprising a compound of the above Formula 1 and a pharmaceutically-acceptable carrier therefor.

10 Another aspect of this invention involves a method for treating an autoimmune disease comprising administering an effective amount of a pharmaceutical composition discussed above to a patient in need of such treatment.

15 Yet another aspect of the instant invention is a method of treating an inflammatory disease comprising administering an effective amount of a pharmaceutical composition discussed above to a patient in need of such treatment.


20 A further aspect of the instant invention is method of treating a neurodegenerative disease comprising administering a pharmaceutically effective amount of a pharmaceutical composition discussed above to a patient in need of such treatment.

25 Yet another aspect of the instant invention is a method of preventing ischemic injury to a patient suffering from a disease associated with ischemic injury comprising administering an effective amount of a

pharmaceutical composition discussed above to a patient in need of such treatment.

# DETAILED DESCRIPTION

5 One aspect of the instant invention is compounds of the Formula 1:



FORMULA 1

wherein:


n is 1 or 2;

10

m is 1 or 2;

A is R<sup>2</sup>CO-, R<sup>3</sup>-O-CO-, or R<sup>4</sup>SO<sub>2</sub>-;

a group of the formula:



further wherein:

R<sup>1</sup> is a hydrogen atom, alkyl or phenylalkyl;

5 R<sup>2</sup> is alkyl, cycloalkyl, (cycloalkyl)alkyl, phenyl, phenylalkyl, substituted phenyl, (substituted phenyl)alkyl, heteroaryl, or (heteroaryl)alkyl;

10 R<sup>3</sup> is alkyl, cycloalkyl, (cycloalkyl)alkyl, phenylalkyl, or (substituted phenyl)alkyl;

R<sup>4</sup> is alkyl, cycloalkyl, (cycloalkyl)alkyl, phenyl, phenylalkyl, substituted phenyl, (substituted phenyl)alkyl, heteroaryl, or (heteroaryl)alkyl;

15 R<sup>5</sup> is alkyl, cycloalkyl, (cycloalkyl)alkyl, phenyl, phenylalkyl, substituted phenyl, (substituted phenyl)alkyl, heteroaryl, or (heteroaryl)alkyl;

20 R<sup>6</sup> is alkyl, cycloalkyl, (cycloalkyl)alkyl, phenylalkyl, or (substituted phenyl)alkyl;


R<sup>7</sup> is alkyl, cycloalkyl, (cycloalkyl)alkyl, phenyl, phenylalkyl, substituted phenyl,

(substituted phenyl)alkyl, heteroaryl, or  
(heteroaryl)alkyl;

$R^8$  is an amino acid side chain chosen from  
the group consisting of natural and  
unnatural amino acids;

B is a hydrogen atom, a deuterium atom, alkyl,  
cycloalkyl, (cycloalkyl)alkyl, phenyl,  
phenylalkyl, (substituted)phenyl,  
(substituted)phenylalkyl, heteroaryl,  
(heteroaryl)alkyl, or halomethyl;

a group of the formula




wherein  $R^9$  is phenyl, phenylalkyl, substituted  
phenyl, (substituted phenyl)alkyl, heteroaryl,  
or (heteroaryl)alkyl; and X is an oxygen or a  
sulfur atom;


a group of the formula:



a group of the formula:



a group of the formula:



wherein R<sup>10</sup> and R<sup>11</sup> are independently selected from a group consisting of alkyl, cycloalkyl, phenyl, substituted phenyl, phenylalkyl, and (substituted phenyl)alkyl;

5 or a pharmaceutically-acceptable salt thereof.

As used in the above formula, the term "alkyl" means substituted or unsubstituted a straight chain or branched C<sub>1</sub> to C<sub>8</sub> carbon chain such as methyl, ethyl, tert-butyl, iso-propyl, n-octyl, and the like. Suitable  
10 substituents include carboxy, protected carboxy, amino, protected amino, halo, hydroxy, protected hydroxy, nitro, cyano, monosubstituted amino, protected monosubstituted amino, disubstituted amino, C<sub>1</sub> to C<sub>7</sub> alkoxy, C<sub>1</sub> to C<sub>7</sub> acyl, C<sub>1</sub> to C<sub>7</sub> acyloxy, and the like.

15 The term "cycloalkyl" means a mono-, bi-, or tricyclic saturated ring that is fully saturated or partially unsaturated. Examples of such a group included cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, cyclooctyl, cis- or trans  
20 decalin, bicyclo[2.2.1]hept-2-ene, cyclohex-1-enyl, cyclopent-1-enyl, 1,4-cyclooctadienyl, and the like.

The term "(cycloalkyl)alkyl" means the above-defined alkyl group substituted for one of the above cycloalkyl rings. Examples of such a group include  
25 (cyclohexyl)methyl, 3-(cyclopropyl)-n-propyl, 5-(cyclopentyl)hexyl, 6-(adamantyl)hexyl, and the like.

The term "substituted phenyl" specifies a phenyl group substituted with one or more, and preferably one or two, moieties chosen from the groups consisting of  
30 halogen, hydroxy, protected hydroxy, cyano, nitro,

trifluoromethyl, C<sub>1</sub> to C<sub>7</sub> alkyl, C<sub>1</sub> to C<sub>7</sub> alkoxy, C<sub>1</sub> to C<sub>7</sub> acyl, C<sub>1</sub> to C<sub>7</sub> acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino, 5 (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, carboxamide, protected carboxamide, N-(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, protected N-(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, N,N-di(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, trifluoromethyl, N-((C<sub>1</sub> to C<sub>6</sub> alkyl)sulfonyl)amino, N- 10 (phenylsulfonyl)amino or phenyl, substituted or unsubstituted, such that, for example, a biphenyl or naphthyl group results.

Examples of the term "substituted phenyl" includes a mono- or di(halo)phenyl group such as 2, 3 or 15 4-chlorophenyl, 2,6-dichlorophenyl, 2,5-dichlorophenyl, 3,4-dichlorophenyl, 2,3 or 4-bromophenyl, 3,4-dibromophenyl, 3-chloro-4-fluorophenyl, 2, 3 or 4-fluorophenyl and the like; a mono or di(hydroxy)phenyl group such as 2, 3, or 4-hydroxyphenyl, 2,4- 20 dihydroxyphenyl, the protected-hydroxy derivatives thereof and the like; a nitrophenyl group such as 2, 3, or 4-nitrophenyl; a cyanophenyl group, for example, 2,3 or 4-cyanophenyl; a mono- or di(alkyl)phenyl group such as 2, 3, or 4-methylphenyl, 2,4-dimethylphenyl, 2, 3 or 25 4-(iso-propyl)phenyl, 2, 3, or 4-ethylphenyl, 2, 3 or 4-(n-propyl)phenyl and the like; a mono or di(alkoxy)phenyl group, for example, 2,6-dimethoxyphenyl, 2, 3 or 4-(iso-propoxy)phenyl, 2, 3 or 4-(t-butoxy)phenyl, 3-ethoxy-4-methoxyphenyl and the like; 2, 3 or 4- 30 trifluoromethylphenyl; a mono- or dicarboxyphenyl or (protected carboxy)phenyl group such as 2, 3 or 4-carboxyphenyl or 2,4-di(protected carboxy)phenyl; a mono- or di(hydroxymethyl)phenyl or (protected hydroxymethyl)phenyl such as 2, 3 or 4-(protect d

hydroxymethyl)phenyl or 3,4-di(hydroxymethyl)phenyl; a  
mono- or di(aminomethyl)phenyl or (protected  
aminomethyl)phenyl such as 2, 3 or 4-(aminomethyl)phenyl  
or 2,4-(protected aminomethyl)phenyl; or a mono- or di(N-  
5 (methylsulfonylamino))phenyl such as 2, 3 or 4-(N-  
(methylsulfonylamino))phenyl. Also, the term  
"substituted phenyl" represents disubstituted phenyl  
groups wherein the substituents are different, for  
example, 3-methyl-4-hydroxyphenyl, 3-chloro-4-  
10 hydroxyphenyl, 2-methoxy-4-bromophenyl, 4-ethyl-2-  
hydroxyphenyl, 3-hydroxy-4-nitrophenyl, 2-hydroxy-4-  
chlorophenyl and the like.

The term "(substituted phenyl)alkyl" means one  
of the above substituted phenyl groups attached to one of  
15 the above-described alkyl groups. Examples of include  
such groups as 2-phenyl-1-chloroethyl, 2-(4'-  
methoxyphenyl)ethyl, 4-(2',6'-dihydroxy phenyl)n-hexyl,  
2-(5'-cyano-3'-methoxyphenyl)n-pentyl, 3-(2',6'-  
dimethylphenyl)n-propyl, 4-chloro-3-aminobenzyl, 6-(4'-  
20 methoxyphenyl)-3-carboxy(n-hexyl), 5-(4'-  
aminomethylphenyl)-3-(aminomethyl)n-pentyl, 5-phenyl-3-  
oxo-n-pent-1-yl, (4-hydroxynaph-2-yl)methyl and the  
like.

The terms "halo" and "halogen" refer to the  
25 fluoro, chloro, bromo or iodo groups. There can be one  
or more halogen, which are the same or different.  
Preferred halogens are chloro and fluoro.

The term "aryl" refers to aromatic five and six  
membered carbocyclic rings. Six membered rings are  
30 preferred.

The term "heteroaryl" denotes optionally substituted five-membered or six-membered rings that have 1 to 4 heteroatoms, such as oxygen, sulfur and/or nitrogen atoms, in particular nitrogen, either alone or in conjunction with sulfur or oxygen ring atoms. These five-membered or six-membered rings are fully unsaturated.

Furthermore, the above optionally substituted five-membered or six-membered rings can optionally be fused to a aromatic 5-membered or 6-membered ring system. For example, the rings can be optionally fused to an aromatic 5-membered or 6-membered ring system such as a pyridine or a triazole system, and preferably to a benzene ring.

The following ring systems are examples of the heterocyclic (whether substituted or unsubstituted) radicals denoted by the term "heteroaryl": thienyl, furyl, pyrrolyl, pyrrolidinyl, imidazolyl, isoxazolyl, triazolyl, thiadiazolyl, oxadiazolyl, tetrazolyl, thiatriazolyl, oxatriazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, oxazinyl, triazinyl, thiadiazinyl, tetrazolo, 1,5-[b]pyridazinyl and purinyl, as well as benzo-fused derivatives, for example, benzoxazolyl, benzthiazolyl, benzimidazolyl and indolyl.

Substituents for the above optionally substituted heteroaryl rings are from one to three halo, trihalomethyl, amino, protected amino, amino salts, mono-substituted amino, di-substituted amino, carboxy, protected carboxy, carboxylate salts, hydroxy, protected hydroxy, salts of a hydroxy group, lower alkoxy, lower alkylthio, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, (cycloalkyl)alkyl, substituted



(cycloalkyl)alkyl, phenyl, substituted phenyl, phenylalkyl, and (substituted phenyl)alkyl. Substituents for the heteroaryl group are as heretofore defined, or in the case of trihalomethyl, can be trifluoromethyl, trichloromethyl, tribromomethyl, or triiodomethyl. As used in conjunction with the above substituents for heteroaryl rings, "lower alkoxy" means a C<sub>1</sub> to C<sub>4</sub> alkoxy group, similarly, "lower alkylthio" means a C<sub>1</sub> to C<sub>4</sub> alkylthio group. The term "substituted alkyl" means the above defined alkyl group substituted from one to three times by a hydroxy, protected hydroxy, amino, protected amino, cyano, halo, trifluoromethyl, mono-substituted amino, di-substituted amino, lower alkoxy, lower alkylthio, carboxy, protected carboxy, or a carboxy, amino, and/or hydroxy salt. As used in conjunction with the substituents for the heteroaryl rings, the terms "substituted (cycloalkyl)alkyl" and "substituted cycloalkyl" are as defined above substituted with the same groups as listed for a "substituted alkyl" group. The term "(monosubstituted)amino" refers to an amino group with one substituent chosen from the group consisting of phenyl, substituted phenyl, alkyl, substituted alkyl, C<sub>1</sub> to C<sub>7</sub> acyl, C<sub>2</sub> to C<sub>7</sub> alkenyl, C<sub>2</sub> to C<sub>7</sub> substituted alkenyl, C<sub>2</sub> to C<sub>7</sub> alkynyl, C<sub>7</sub> to C<sub>16</sub> alkylaryl, C<sub>7</sub> to C<sub>16</sub> substituted alkylaryl and heteroaryl group. The (monosubstituted)amino can additionally have an amino-protecting group as encompassed by the term "protected (monosubstituted)amino." The term "(disubstituted)amino" refers to amino groups with two substituents chosen from the group consisting of phenyl, substituted phenyl, alkyl, substituted alkyl, C<sub>1</sub> to C<sub>7</sub> acyl, C<sub>2</sub> to C<sub>7</sub> alkenyl, C<sub>2</sub> to C<sub>7</sub> alkynyl, C<sub>7</sub> to C<sub>16</sub> alkylaryl, C<sub>7</sub> to C<sub>16</sub> substituted alkylaryl and heteroaryl. The two substituents can be the same or different. The term "heteroaryl(alkyl)" denotes an alkyl group as

defined above, substituted at any position by a heteroaryl group, as above defined.

The term "pharmaceutically-acceptable salt" encompasses those salts that form with the carboxylate anions and includes salts formed with the organic and inorganic cations such as those chosen from the alkali and alkaline earth metals, (for example, lithium, sodium, potassium, magnesium, barium and calcium); ammonium; and the organic cations (for example, dibenzylammonium, benzylammonium, 2-hydroxyethylammonium, bis(2-hydroxyethyl)ammonium, phenylethylbenzylammonium, dibenzylethylenediammonium, and like cations.) Other cations encompassed by the above term include the protonated form of procaine, quinine and N-methylglucosamine, the protonated forms of basic amino acids such as glycine, ornithine, histidine, phenylglycine, lysine, and arginine, and acetic acid-like counter-ions such as acetate and trifluoroacetate. Furthermore, any zwitterionic form of the instant compounds formed by a carboxylic acid and an amino group is referred to by this term. A preferred cation for the carboxylate anion is the sodium cation. Furthermore, the term includes salts that form by standard acid-base reactions with basic groups (such as amino groups) and includes organic or inorganic acids. Such acids include hydrochloric, sulfuric, phosphoric, acetic, succinic, citric, lactic, maleic, fumaric, palmitic, cholic, pamoic, mucic, D-glutamic, D-camphoric, glutaric, phthalic, tartaric, lauric, stearic, salicylic, methanesulfonic, benzenesulfonic, sorbic, picric, benzoic, cinnamic, and the like acids.

The compounds of Formula 1 may also exist as solvates and hydrates. Thus, these compounds may

crystallize with, for example, waters of hydration, or one, a number of, or any fraction thereof of molecules of the mother liquor solvent. The solvates and hydrates of such compounds are included within the scope of this invention.

The term "carboxy-protecting group" as used herein refers to one of the ester derivatives of the carboxylic acid group commonly employed to block or protect the carboxylic acid group while reactions are carried out on other functional groups on the compound. Examples of such carboxylic acid protecting groups include t-butyl, 4-nitrobenzyl, 4-methoxybenzyl, 3,4-dimethoxybenzyl, 2,4-dimethoxybenzyl, 2,4,6-trimethoxybenzyl, 2,4,6-trimethylbenzyl, pentamethylbenzyl, 3,4-methylenedioxybenzyl, benzhydryl, 4,4'-dimethoxytrityl, 4,4',4"-trimethoxytrityl, 2-phenylpropyl, trimethylsilyl, t-butyldimethylsilyl, phenacyl, 2,2,2-trichloroethyl,  $\beta$ -(trimethylsilyl)ethyl,  $\beta$ -(di(n-butyl)methylsilyl)ethyl, p-toluenesulfonylethyl, 4-nitrobenzylsulfonylethyl, allyl, cinnamyl, 1-(trimethylsilylmethyl)-propenyl and like moieties. The species of carboxy-protecting group employed is not critical so long as the derivatized carboxylic acid is stable to the conditions of subsequent reaction(s) and can be removed at the appropriate point without disrupting the remainder of the molecule. Further examples of these groups are found in C.B. Reese and E. Haslam, "Protective Groups in Organic Chemistry," J.G.W. McOmie, Ed., Plenum Press, New York, NY, 1973, Chapter 5, respectively, and T.W. Greene and P.G.M. Wuts, "Protective Groups in Organic Synthesis," 2nd ed., John Wiley and Sons, New York, NY, 1991, Chapter 5, each of which is incorporated herein by reference. A related term is "protected carboxy," which refers to a carboxy

group substituted with one of the above carboxy-protecting groups.

The term "hydroxy-protecting group" refers to readily cleavable groups bonded to hydroxyl groups, such as the tetrahydropyranyl, 2-methoxyprop-2-yl, 1-ethoxyeth-1-yl, methoxymethyl,  $\beta$ -methoxyethoxymethyl, methylthiomethyl, t-butyl, t-amyl, trityl, 4-methoxytrityl, 4,4'-dimethoxytrityl, 4,4',4"-trimethoxytrityl, benzyl, allyl, trimethylsilyl, (t-butyl)dimethylsilyl, 2,2,2-trichloroethoxycarbonyl groups and the like.

Further examples of hydroxy-protecting groups are described by C.B. Reese and E. Haslam, "Protective Groups in Organic Chemistry," J.G.W. McOmie, Ed., Plenum Press, New York, NY, 1973, Chapters 3 and 4, respectively, and T.W. Greene and P.G.M. Wuts, "Protective Groups in Organic Synthesis," Second Edition, John Wiley and Sons, New York, NY, 1991, Chapters 2 and 3. A preferred hydroxy-protecting group is the tert-butyl group. The related term "protected hydroxy" denotes a hydroxy group bonded to one of the above hydroxy protecting groups.

The term "amino-protecting group" as used herein refers to substituents of the amino group commonly employed to block or protect the amino functionality while reacting other functional groups of the molecule. The term "protected (monosubstituted)amino" means there is an amino-protecting group on the monosubstituted amino nitrogen atom.

Examples of such amino-protecting groups include the formyl ("For") group, the trityl group, the

phthalimido group, the trichloroacetyl group, the trifluoroacetyl group, the chloroacetyl, bromoacetyl, and iodoacetyl groups, urethane-type blocking groups, such as t-butoxycarbonyl ("Boc"), 2-(4-biphenyl)propyl-2-oxycarbonyl ("Bpoc"), 2-phenylpropyl-2-oxycarbonyl ("Poc"), 2-(4-xenyl)isopropoxycarbonyl, 1,1-diphenylethyl-1-oxycarbonyl, 1,1-diphenylpropyl-1-oxycarbonyl, 2-(3,5-dimethoxyphenyl)propyl-2-oxycarbonyl ("Ddz"), 2-(p-toluy)propyl-2-oxycarbonyl, cyclopentanyloxycarbonyl, 1-methylcyclopentanyloxycarbonyl, cyclohexanyloxycarbonyl, 1-methylcyclohexanyloxycarbonyl, 2-methylcyclohexanyloxycarbonyl, 2-(4-toluy)sulfonyl)ethoxycarbonyl, 2-(methylsulfonyl)ethoxycarbonyl, 2-(triphenylphosphino)-ethoxycarbonyl, 9-fluorenylmethoxycarbonyl ("Fmoc"), 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, 1-(trimethylsilylmethyl)prop-1-enyloxycarbonyl, 5-benzisoxalylmethoxycarbonyl, 4-acetoxybenzyloxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-ethynyl-2-propoxycarbonyl, cyclopropylmethoxycarbonyl, isobornyloxycarbonyl, 1-piperidyloxycarbonyl, benzyloxycarbonyl ("Cbz"), 4-phenylbenzyloxycarbonyl, 2-methylbenzyloxy-carbonyl,  $\alpha$ -2,4,5,-tetramethylbenzyloxycarbonyl ("Tmz"), 4-methoxybenzyloxycarbonyl, 4-fluorobenzyloxycarbonyl, 4-chlorobenzyloxycarbonyl, 3-chlorobenzyloxycarbonyl, 2-chlorobenzyloxycarbonyl, 2,4-dichlorobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 3-bromobenzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-cyanobenzyloxycarbonyl, 4-(decyloxy)benzyloxycarbonyl and the like; the benzoylmethylsulfonyl group, 2,2,5,7,8-pentamethylchroman-6-sulfonyl group ("PMC") dithiasuccinoyl ("Dts"), the 2-(nitro)phenylsulfenyl

group ("Nps"), the diphenyl-phosphine oxide group and like amino-protecting groups. The species of amino-protecting group employed is not critical so long as the derivatized amino group is stable to the conditions of the subsequent reaction(s) and can be removed at the appropriate point without disrupting the remainder of the molecule. Preferred amino-protecting groups are Boc, Cbz and Fmoc. Further examples of amino-protecting groups embraced by the above term are well known in organic synthesis and the peptide art and are described by, for example, T.W. Greene and P.G.M. Wuts, "Protective Groups in Organic Synthesis," 2nd ed., John Wiley and Sons, New York, NY, 1991, Chapter 7, M. Bodanzsky, "Principles of Peptide Synthesis," 1st and 2nd revised ed., Springer-Verlag, New York, NY, 1984 and 1993, and J.M. Stewart and J.D. Young, "Solid Phase Peptide Synthesis," 2nd ed., Pierce Chemical Co., Rockford, IL, 1984, E. Atherton and R.C. Shephard, "Solid Phase Peptide Synthesis - A Practical Approach" IRL Press, Oxford, England (1989), each of which is incorporated herein by reference. The related term "protected amino" defines an amino group substituted with an amino-protecting group discussed above.

The terms "natural and unnatural amino acids" ( $\alpha$ -amino acid) refers to both the naturally occurring amino acids and other "non-protein"  $\alpha$ -amino acids commonly utilized by those in the peptide chemistry arts when preparing synthetic analogues of naturally occurring peptides, including D and L forms. The naturally occurring amino acids are glycine, alanine, valine, leucine, isoleucine, serine, methionine, threonine, phenylalanine, tyrosine, tryptophan, cysteine, proline, histidine, aspartic acid, asparagine, glutamic acid, glutamine,  $\gamma$ -carboxyglutamic acid, arginine, ornithine

and lysine. Examples of "non-protein" alpha-amino acids include hydroxylysine, citrulline, kynurenine, (4-aminophenyl)alanine, 3-(2'-naphthyl)alanine, 3-(1'-naphthyl)alanine, methionine sulfone, (t-butyl)alanine, (t-butyl)glycine, 4-hydroxyphenylglycine, aminoalanine, phenylglycine, vinylalanine, propargyl-glycine, 1,2,4-triazolo-3-alanine, thyronine, 6-hydroxytryptophan, 5-hydroxytryptophan, 3-hydroxykynurenine, 3-aminotyrosine, trifluoromethyl-alanine, 2-thienylalanine, (2-(4-pyridyl)ethyl)cysteine, 3,4-dimethoxy-phenylalanine, 3-(2'-thiazolyl)alanine, ibotenic acid, 1-amino-1-cyclopentane-carboxylic acid, 1-amino-1-cyclohexanecarboxylic acid, quisqualic acid, 3-(trifluoromethylphenyl)alanine, (cyclohexyl)glycine, thiohistidine, 3-methoxytyrosine, elastatinal, norleucine, norvaline, alloisoleucine, homoarginine, thioproline, dehydroproline, hydroxyproline, homoproline,  $\alpha$ -amino-n-butyric acid, cyclohexylalanine, 2-amino-3-phenylbutyric acid, phenylalanine substituted at the ortho, meta, or para position of the phenyl moiety with one or two of the following: a ( $C_1$  to  $C_4$ )alkyl, a ( $C_1$  to  $C_4$ )alkoxy, halogen or nitro groups or substituted with a methylenedioxy group;  $\beta$ -2- and 3-thienylalanine,  $\beta$ -2- and 3-furanylalanine,  $\beta$ -2-, 3- and 4-pyridylalanine,  $\beta$ -(benzothienyl-2- and 3-yl)alanine,  $\beta$ -(1- and 2-naphthyl)alanine, O-alkylated derivatives of serine, threonine or tyrosine, S-alkylated cysteine, S-alkylated homocysteine, O-sulfate, O-phosphate and O-carboxylate esters of tyrosine, 3-(sulfo)tyrosine, 3-(carboxy)tyrosine, 3-(phospho)tyrosine, the 4-methane sulfonic acid ester of tyrosine, 4-methane phosphonic acid ester of tyrosine, 3,5-diiodotyrosine, 3-nitrotyrosine,  $\epsilon$ -alkyl lysine, and delta-alkyl ornithine. Any of these  $\alpha$ -amino acids may be substituted with a methyl group at the alpha position, a halogen at any

aromatic residue on the  $\alpha$ -amino side chain, or an appropriate protective group at the O, N, or S atoms of the side chain residues. Appropriate protective groups are discussed above.

5

Depending on the choice of solvent and other conditions known to the practitioner skilled in the art, compounds of this invention may also take the hemi-ketal, hemi-acetal, ketal or acetal form, which forms are  
10 included in the instant invention.

In addition, it should be understood that the equilibrium forms of the compounds of this invention may include tautomeric forms. All such forms of these compounds are expressly included in the present  
15 invention.

Also, it will be understood by those skilled in the art that when B in Formula 1 is a hydrogen atom, a semicarbazone may be formed with the resulting aldehyde.  
20 Such semicarbazones are also included as compounds of Formula 1, as well as the pharmaceutical compositions containing those compounds. Such semicarbazones include, for example, semicarbazone derivative of the optimal groups and embodiments of the 4-oxo butanoic acid  
25 derivatives of the oxoazepino indole and oxo-azepino quinoline compounds set forth below.

An optimal group of compounds of Formula 1 exists when in the above Formula n is 1, and more so when m is 1. These compounds will be referred to herein as  
30 the "oxoazepino indole" compounds.

An optimal group of oxoazepino indole compounds exists when B in Formula 1 is a hydrogen atom, compounds



referred to herein as "4-oxobutanoic derivatives" . One embodiment of note of such 4-oxobutanoic acid derivatives occurs when A in Formula 1 is a group of the formula  $R^2CO-$ , more so when  $R^2$  is 2-(carboxy)eth-1-yl, 2-(phenyl)eth-1-yl, methyl, naph-1-yl or phenyl, and especially so when  $R^1$  is a hydrogen atom. Another embodiment of 4-oxobutanoic acid derivatives exists when A is a group of the formula  $R^5-CO-NH-CHR^8-CO-$ , more so when  $R^5$  is a methyl group and  $R^8$  is a group of the formula  $-CH_2COOH$ , and especially so when  $R^1$  is a hydrogen atom. Yet another embodiment of 4-oxobutanoic acid derivatives of note has A as a group of the formula  $R^6-O-CO-NH-CHR^8-CO-$ , further wherein  $R^6$  is a benzyl group and  $R^8$  is a group of the formula  $-CH_2-COOH$ , and especially so when  $R^1$  is a hydrogen atom. Still another embodiment of the 4-oxobutanoic derivatives occurs when A is a group of the formula  $R^3-O-CO-$  wherein  $R^3$  is benzyl, and especially so when  $R^1$  is a hydrogen atom.

Another optimal group of oxoazepino indole compounds occurs when B in Formula 1 is a monofluoromethyl group and are thus referred to as "monofluoromethyl derivatives." A noteworthy embodiment of monofluoromethyl derivatives has A as a group of the formula  $R^3-O-CO-$ , more so when  $R^3$  is a benzyl group, and especially so when  $R^1$  is a hydrogen atom.

A further optimal group of oxoazepino indole compounds occurs when B in Formula 1 is a group of the formula  $-CH_2-O-PO(R^{10})R^{11}$ . This group of compounds is referred to herein as "phosphinyloxy derivatives". A group of noteworthy phosphinyloxy derivatives has  $R^{10}$  and  $R^{11}$  each as phenyl groups. An embodiment of such diphenyl phosphinyloxy compounds exists wherein A in Formula 1 is a group of the formula

$R^3$ -O-CO- wherein  $R^3$  is benzyl, and especially so when  $R^1$  is a hydrogen atom.


Another optimal group of compounds of Formula 1 exists when in the above Formula n is 2, and more so when  
5 m is 1. These compounds will be referred to herein as the "oxoazepino quinoline" compounds.

An exemplary group of oxoazepino quinoline compounds occurs when B in Formula 1 is a hydrogen atom, more so when A is a group of the formula  $R^3$ -O-CO- wherein  
10  $R^3$  is benzyl, and especially so when  $R^1$  is a hydrogen atom.

It should be understood that the compounds of this invention may be modified by appropriate functionalities to enhance selective biological  
15 properties. Such modifications are known in the art and include those which increase biological penetration into a given biological system (e.g., blood, lymphatic system, central nervous system), increase oral availability, increase solubility to allow administration by injection,  
20 alter metabolism and alter rate of exertion. In addition, the compounds may be altered to pro-drug form such that the desired compound is created in the body of the patient as the result of the action of metabolic or other biochemical processes on the pro-drug. Some  
25 examples of pro-drug forms include ketal, acetal, oxime, and hydrazone forms of compounds which contain ketone or aldehyde groups, especially where they occur in the A group or the modified aspartic or glutamic residues attached to the tricyclic nucleus of the compounds of  
30 this invention.


The compounds of Formula 1 of this invention may be synthesized using conventional techniques. Advantageously, these compounds are conveniently synthesized from readily available starting materials.

5 Thus, compounds of the instant invention can be synthesized in general by combining a tricyclic nucleus set forth below in Formula 2:




FORMULA 2


with the modified aspartic and glutamic acid residues of  
10 Formula 3a-d:




FORMULA 3a;



FORMULA 3b;



FORMULA 3c; or



FORMULA 3d.


in the presence of a standard peptide coupling agents  
 such as dicyclohexylcarbodiimide(DCC)/1-  
 5 hydroxybenzotriazole (HOBt), BOP reagent, pyBOP, TBTU,  
 EEDQ, 1-ethyl(3,3'-dimethyl-1'-  
 aminopropyl)carbodiimide(EDAC)/HOBt, and the like, as  
 discussed in J. Jones, "Amino Acid and Peptide

Synthesis," Steven G. Davis ed., Oxford University Press, Oxford, pp. 25-41 (1992), herein incorporated by reference. In the above formula, APG is an amino protecting group. The amino protecting group is then  
5 removed and the resulting amine is combined with the substituted acyl group of Formula 4:

**FORMULA 4**

or the sulfonyl group of Formula 5:

10

**FORMULA 5**

In the above formulas,  $R^1$  is as defined above, and  $R^C$  is  $R^2$ ,  $R^3-O$ ,  $R^4$ , or any of the side chains containing  $R^8$  as defined for group A in Formula 1. Of  
15 course, such moieties would have any hydroxy, carboxy or amino groups in the protected form so as not to interfere with the coupling reaction (Formula 3a-d), the acylation reaction (Formula 4) or the sulfonation reaction (Formula  
20 5). X in the above Formulas represents a facile leaving group for the acylation or sulfonation reactions.

In the case where the coupling reaction was carried out with the amino alcohol of Formula 3c, the alcohol moiety must be oxidized to the corresponding carbonyl compound prior to removal of the protecting  
25 groups. Preferred methods for the oxidation reaction include Swern oxidation (oxalyl chloride-dimethyl sulfoxide, methylene chloride at  $-78^\circ\text{C}$  followed by

triethylamine; and Dess-Martin oxidation (Dess-Martin periodinane, t-butanol, and methylene chloride.) The protecting groups contained in substructures of the Formula 2 and 3a-d are removed by methods well known in the art.

The tricyclic nucleus of Formula 2 is synthesized by methods known in the art. For example, see D.S. Karanewsky, U.S. Patent No. 5,504,080 issued April 2, 1996; J.A. Robl et al., Tetrahedron Letters, 36:1593-1596 (1995); and S. De Lombaert et al., Tetrahedron Letters, 35:7513-7516 (1994), all of which are incorporated herein by reference.

The modified aspartic or glutamic acid for Formula 3a-d can be elaborated by methods well known in the art. See, for example, European Patent Application 519,748; PCT Patent Application No. PCT/EP92/02472; PCT Patent Application No. PCT/US91/06595; PCT Patent Application No. PCT/US91/02339; European Patent Application No. 623,592; World Patent Application No. WO 93/09135; PCT Patent Application No. PCT/US94/08868; European Patent Application No. 623,606; European Patent Application No. 618,223; European Patent Application No. 533,226; European Patent Application No. 528,487; European Patent Application No. 618,233; PCT Patent Application No. PCT/EP92/02472; World Patent Application No. WO 93/09135; PCT Patent Application No. PCT/US93/03589; and PCT Patent Application No. PCT/US93/00481, all of which are herein incorporated by reference.

The acyl group of Formula 4 and the corresponding R<sup>4</sup>SO<sub>2</sub> groups are also synthesized by methods well known in the art. See, for example, U.S. Patent No.

5,504,080, issued April 2, 1996, herein incorporated by reference. While this group can be elaborated once bonded to the tricyclic nucleus, it is preferable that it be intact before being attached to the nucleus.

- 5           Once the side chains of Formula 3 and Formula 4 or Formula 5 are bonded to the tricyclic nucleus of Formula 2, one skilled in the art would usually remove any amino, hydroxy, or carboxy-protecting groups to enhance the activity of the synthesized molecule.
- 10           Pharmaceutical compositions of this invention comprise any of the compounds of Formula 1, and pharmaceutically acceptable salts thereof, with any pharmaceutically acceptable carrier, adjuvant or vehicle (hereinafter collectively referred to as
- 15 "pharmaceutically-acceptable carriers"). Pharmaceutically acceptable carriers, adjuvants and vehicles that may be used in the pharmaceutical compositions of this invention include, but are not limited to, ion exchange, alumina, aluminum stearate, lecithin, serum proteins, such as
- 20 human serum albumin, buffer substances such as the various phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate,
- 25 potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyarylates, waxes, polyethylene-polyoxypropylene-block polymers,
- 30 polyethylene glycol and wool fat.

An optimal group of pharmaceutical compositions of Formula 1 exists when in the above Formula n is 1, and

more so when  $n$  is 1. These compositions will be referred to herein as the "oxoazepino indole" compositions.

An optimal group of oxoazepino indole compositions exists when B in Formula 1 is a hydrogen atom, compositions referred to herein as "4-oxobutanoic derivatives". One embodiment of note of such 4-oxobutanoic acid derivatives occurs when A in Formula 1 is a group of the formula  $R^2CO-$ , more so when  $R^2$  is 2-(carboxy)eth-1-yl, 2-(phenyl)eth-1-yl, methyl, naphth-1-yl or phenyl, and especially so when  $R^1$  is a hydrogen atom.

Another embodiment of 4-oxobutanoic acid derivatives exists when A is a group of the formula  $R^5-CO-NH-CHR^8-CO-$ , more so when  $R^5$  is a methyl group and  $R^8$  is a group of the formula  $-CH_2COOH$ , and especially so when  $R^1$  is a hydrogen atom. Yet another embodiment of 4-oxobutanoic acid derivatives of note has A as a group of the formula  $R^6-O-CO-NH-CHR^8-CO-$ , further wherein  $R^6$  is a benzyl group and  $R^8$  is a group of the formula  $-CH_2-COOH$ , and especially so when  $R^1$  is a hydrogen atom. Still another embodiment of the 4-oxobutanoic derivatives occurs when A is a group of the formula  $R^3-O-CO-$  wherein  $R^3$  is benzyl, and especially so when  $R^1$  is a hydrogen atom.

Another optimal group of oxoazepino indole compositions occurs when B in Formula 1 is a monofluoromethyl group and are thus referred to as "monofluoromethyl derivatives." A noteworthy embodiment of monofluoromethyl derivatives has A as a group of the formula  $R^3-O-CO-$ , more so when  $R^3$  is a benzyl group, and especially so when  $R^1$  is a hydrogen atom.

A further optimal group of oxoazepino indole compositions occurs when B in Formula 1 is a group of the



formula  $-\text{CH}_2-\text{O}-\text{PO}(\text{R}^{10})\text{R}^{11}$ . This group of compositions is referred to herein as "phosphinyloxy derivatives". A group of noteworthy phosphinyloxy derivatives has  $\text{R}^{10}$  and  $\text{R}^{11}$  each as phenyl groups. An embodiment of such diphenyl  
5 phosphinyloxy compositions exists wherein A in Formula 1 is a group of the formula  $\text{R}^3-\text{O}-\text{CO}-$  wherein  $\text{R}^3$  is benzyl, and especially so when  $\text{R}^1$  is a hydrogen atom.

Another optimal group of pharmaceutical compositions of Formula 1 exists when in the above  
10 Formula n is 2, and more so when m is 1. These compositions will be referred to herein as the "oxoazepino quinoline" compositions.

An exemplary group of oxoazepino quinoline compositions occurs when B in Formula 1 is a hydrogen  
15 atom, more so when A is a group of the formula  $\text{R}^3-\text{O}-\text{CO}-$  wherein  $\text{R}^3$  is benzyl, and especially so when  $\text{R}^1$  is a hydrogen atom.

The pharmaceutical compositions of this  
20 invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. Oral and parenteral administration are preferred. The term "parenteral" as used herein includes subcutaneous,  
25 intracutaneous, intravenous, intramuscular, intra-articular, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or infusion techniques.

The pharmaceutical compositions may be in the  
30 form of a sterile injectable preparation, for example, as a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to techniques

known in the art using suitable dispersing or wetting agents (such as, for example, Tween 80) and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are mannitol, water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or diglycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant such as Ph. Hely or a similar alcohol.

The pharmaceutical compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, and aqueous suspensions and solutions. In the case of tablets for oral use, carrier which are commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in capsule form useful diluents include lactose and dried corn starch. When aqueous suspension are administered orally, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening and/or flavoring and/or coloring agents may be added.

The pharmaceutical compositions of this invention may also be administered in the form of suppositories for rectal administration. These compositions can be prepared by mixing a compound of this invention with a suitable non-irritating excipient which is solid at room temperature but liquid at the rectal temperature and therefore will melt in the rectum to release the active components. Such materials include, but are not limited to, cocoa butter, beeswax and polyethylene glycols.

Topical administration of the pharmaceutical compositions of this invention is especially useful when the desired treatment involves areas or organs readily accessible to topical application. For application topically to the skin, the pharmaceutical composition should be formulated with a suitable ointment containing the active components suspended or dissolved in a carrier. Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petroleum, white petroleum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water. Alternatively, the pharmaceutical composition can be formulated with a suitable lotion or cream containing the active compound suspended or dissolved in a carrier. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water. The pharmaceutical compositions of this invention may also be topically applied to the lower intestinal tract by rectal suppository formulation or in a suitable enema formulation. Topically-transdermal patches are also included in this invention.

The pharmaceutical compositions of this invention may be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other solubilizing or dispersing agents known in the art.

10 The pharmaceutical compositions of this invention may be employed in a conventional manner for the treatment of diseases which are mediated by IL-1 in mammals. Such methods of treatment, their dosage levels and requirements may be selected by those of ordinary skill in the art from available methods and techniques. For example, a pharmaceutical composition of this invention may be administered to a patient suffering from an IL-1 mediated disease in a pharmaceutically acceptable manner and in an amount effective to lessen the severity of that disease.

In addition, the compounds of this invention may be used in combination with either conventional anti-inflammatory agents or with matrix metalloprotease inhibitors, lipoxxygenase inhibitors and antagonists of cytokines other than IL-1 $\beta$ .

The compounds of this invention can also be administered in combination with immunomodulators (e.g., bropirimine, anti-human alpha interferon antibody, IL-2, GM-CSF, methionine enkephalin, interferon alpha, diethyldithiocarbamate, tumor necrosis factor, naltrexons and rEPO) or with prostaglandins, to prevent or combat IL-1-mediated disease symptoms such as inflammation.

When the compounds of this invention are administered in combination therapies with other agents, they may be administered sequentially or concurrently to the patient. Alternatively, pharmaceutical compositions  
5 according to this invention may be comprised of a combination of a compound of Formula 1 and another therapeutic or prophylactic agent.

The disease states which may be treated or prevented by the instant pharmaceutical compositions  
10 include, but are not limited to, inflammatory diseases, autoimmune diseases and neurodegenerative diseases, and for inhibiting unwanted apoptosis involved in ischemic injury, such as ischemic injury to the heart (e.g., myocardial infarction), brain (e.g., stroke), and kidney  
15 (e.g., ischemic kidney disease). Methods of administering an effective amount of the above-described pharmaceutical compositions to mammals, also referred to herein as patients, in need of such treatment (that is, those suffering from inflammatory diseases, autoimmune  
20 diseases, and neurodegenerative diseases,) are additional aspects of the instant invention.

Yet another aspect of the instant invention is a method of preventing ischemic injury to a patient suffering from a disease associated with ischemic injury  
25 comprising administering an effective amount of a pharmaceutical composition discussed above to a patient in need of such treatment.

Also, each of the methods directed to methods for treating inflammatory diseases, autoimmune diseases,  
30 neurodegenerative disease, and preventing ischemic injury encompass using any of the optimal groups and embodiments of pharmaceutical compositions set forth above.

Inflammatory disease which may be treated or prevented include, for example, septic shock, septicemia, and adult respiratory distress syndrome. Target autoimmune diseases include, for example, rheumatoid, 5 arthritis, systemic lupus erythematosus, scleroderma, chronic thyroiditis, Graves' disease, autoimmune gastritis, insulin-dependent diabetes mellitus, autoimmune hemolytic anemia, autoimmune neutropenia, thrombocytopenia, chronic active hepatitis, myasthenia 10 gravis and multiple sclerosis. Target neurodegenerative diseases include, for example, amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, and primary lateral sclerosis. The pharmaceutical compositions of this invention may also be used to 15 promote wound healing. Target diseases associated with harmful, thus unwanted apoptosis, in other words, those associated with ischemic injury, includes myocardial infarction, stroke, and ischemic kidney disease. The pharmaceutical compositions of this invention may also be 20 used to treat infectious diseases, especially those involved with viral infections.

The term "effective amount" refers to dosage levels of the order of from about 0.05 mg to about 140 mg 25 per kilogram of body weight per day for use in the treatment of the above-indicated conditions (about 2.5 mg to about 7 gms. per patient per day). For example, inflammation may be effectively treated by the administration of from about 0.01 to 50 mg of the 30 compound per kilogram of body weight per day (about 0.5 mg to about 3.5 gms per patient per day).

The amount of the compounds of Formula 1 that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host

treated and the particular mode of administration. For example, a formulation intended for the oral administration of humans may contain from 0.5 mg to 5 gm of a compound of Formula 1 compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95 percent of the total composition. Dosage unit forms will generally contain between from about 1 mg to about 500 mg of an active compound of Formula 1.

10           It will be understood, however, that the specific "effective amount" for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of  
15 administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy.

          Although this invention focuses on the use of the compounds disclosed herein for preventing and  
20 treating IL-1-mediated diseases, the compounds of this invention can also be used as inhibitory agents for other cysteine proteases.

          The compounds of this invention are also useful  
25 as commercial reagents which effectively bind to the ICE/ced-3 family of cysteine protease or other cysteine proteases. As commercial reagents, the compounds of this invention, and their derivatives, may be used to block proteolysis of a target peptide or may be derivatized to  
30 bind to a stable resin as a tethered substrate for affinity chromatography applications. These and other uses which characterize commercial cystine protease

inhibitors will be evident to those of ordinary skill in the art.


ew

In order that this invention be more fully understood, the following examples are set forth. These examples are for the purpose of illustration only and are not to be construed as limiting the scope of the invention in any way.

10 In the following Examples, proton NMR spectra were obtained at 300 MHz; chemical shifts are quoted downfield from internal tetramethylsilane.

### PREPARATION 1

15




**Preparation of (2S-cis)-5-Benzoyloxycarbonylamino-  
1,2,4,5,6,7-Hexahydro-4-Oxazepino[3,2,1-hi]indole-2-  
Carboxylic Acid, Ethyl Ester**

To a solution of (2S-cis)-5-amino-1,2,4,5,6,7-



- hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carboxylic acid, ethyl ester (0.437 g, 1.73 mmol, prepared as described in Tetrahedron Letters 36, pp. 1593-1596 (1995) and U.S. Patent 5,504,080 (April 2, 1996)) in methylene chloride
- 5 (4 mL) stirring at 0°C was added benzyl chloroformate (0.370 mL, 2.6 mmol) and triethylamine (0.724 mL, 5.2 mmol) and the resulting mixture was stirred under nitrogen for 45 minutes. The reaction was quenched with water then partitioned between ethyl acetate and 5%
- 10 aqueous potassium bisulfate solution. The aqueous layer was back-extracted two times with ethyl acetate, then the combined organic layers were washed with saturated sodium chloride solution, dried over sodium sulfate and evaporated to dryness. Purification of the crude product
- 15 by flash chromatography on silica gel (S/P brand silica gel 60Å, 230-400 mesh ASTM) eluting with ethyl acetate-hexane (2:1) gave 0.558 g (68%) of crude product. Trituration with ethyl acetate-hexane (1:4) gave 0.480 g of the title compound as white solid; m.p.: 139-140°C.
- 20 TLC (ethyl acetate-hexane, 2:1):  $R_f$ =0.6;  $^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.35-7.30 (m, 5H), 7.02-6.94 (m, 3H), 6.17 (d,  $J$ =5.4 Hz, 1H), 4.15 (q,  $J$ =7.1 Hz, 2H), 3.46 (dd,  $J$ =11.0, 16.7 Hz, 1H), 3.29 (m, 1H), 3.10 (d,  $J$ =116.5, 2H), 2.35 (m, 1H), 2.16 (m, 1H), 1.23 (t,  $J$ =7.2 Hz, 3H).




**Preparation of (2S-cis)-5-Benzyloxycarbonylamino-1,2,4,5,6,7-Hexahydro-4-Oxoazepino[3,2,1-hi]indole-2-Carboxylic Acid**

- 5 To a solution of (2S-cis)-5-benzyloxycarbonylamino-1,2,4,5,6,7-hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carboxylic acid, ethyl ester, (0.428g, 1.05 mmol) in 1,4-dioxane (7.5 mL) and water (2.5 mL) was added 1M aqueous lithium hydroxide
- 10 (1.6 mL, 1.6 mmol) and the resulting mixture was stirred at room temperature under nitrogen for 30 minutes. The reaction mixture was acidified to pH 3 with a 5% aqueous potassium bisulfate sodium chloride solution. The aqueous layer was back-extracted two times with ethyl
- 15 acetate, and the combined organic layers were dried over sodium sulfate and evaporated to dryness to yield 0.395 g (99%) of title compound as a fine white solid; m.p.: 188-189°C. TLC (methylene chloride-methanol-acetic acid, 9:1:1):  $R_f$ =0.55;  $^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ )  $\delta$  7.34-7.26 (m, 5H), 7.07-6.97 (m, 3H), 6.08 (d,  $J$ =5.7 Hz, 1H), 5.25 (dd,  $J$ =3.2, 9.8 Hz, 1H), 5.10 (s, 2H), 4.30 (m, 1H), 3.36 (m,
- 20

1H), 3.26 (m, 2H), 3.06 (d, J=12.0 Hz, 1H), 2.36 (m, 1H), 2.09 (m, 1H).

### PREPARATION 3


5



#### **Preparation of (3R,S-cis)-6-Benzyloxycarbonylamino-5-oxo-2,3,4,5,6,7,8-hexahydro-1H-azepino[3,2,1-hi]quinoline-3-carboxylic acid, methyl ester**

To a solution of (3R,S-cis)-6-Amino-5-oxo-2,3,4,5,6,7,8-hexahydro-1H-azepino[3,2,1-hi]quinoline-3-carboxylic acid, methyl ester (0.570 g, 2.1 mmol, prepared as described in Tetrahedron Letters 36, pp. 1593-1596 (1995) and U.S. Patent 5,504,080 (April 2, 1996)) in methylene chloride (6 mL) stirring at 0°C was added benzyl chloroformate (0.6 mL, 4.2 mmol) and triethylamine (1.2 mL, 8.4 mmol) and the resulting mixture was stirred under nitrogen for 30 minutes. The reaction was quenched with water then partitioned between ethyl acetate and 5% aqueous potassium bisulfate solution. The aqueous layer was back extracted two times with ethyl acetate, then the combined organic layers were

washed with saturated sodium chloride solution, dried (sodium sulfat ) and evaporated to dryness. Purification of the crude product by flash chromatography on silica gel (S/P brand silica gel 60Å, 230-400 mesh ASTM) eluting  
5 with ethyl acetate-hexane (2:1) gave 0.643 g (76%) of of the title compound as a white foam. TLC (methylene chloride-methanol, 95:5)  $R_f=0.8$ .  $^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ )  
8 7.36-7.25 (m, 5H), 7.13-7.02 (m, 3H), 5.67 (d,  $J=7.8$  Hz, 1H), 5.02 (t,  $J=9.15, 18.3$  Hz, 2H), 4.34 ( m, 1H),  
10 3.70 (s, 3H), 3.16 (m, 1H), 2.69-2.56 (m, 5H), 2.06 (m, 1H). Mass spectrum:  $m/z$  408 ( $\text{M}+\text{H}$ ).


PREPARATION 4

Preparation of (3R,S-cis)-6-Benzyloxycarbonylamino-5-oxo-  
2,3,4,5,6,7,8-hexahydro-1H-azepino[3,2,1-hi]quinoline-3-  
5 carboxylic acid

To a solution of (3R,S-cis)-6-Benzyloxycarbonylamino-5-oxo-2,3,4,5,6,7,8-hexahydro-1H-azepino[3,2,1-hi]quinoline-3-carboxylic acid, methyl ester (0.622g, 1.53 mmol) in 1,4-dioxane (10.5 mL) and  
10 water (3.5 mL) was added 1M aqueous lithium hydroxide (2.3 mL, 2.3 mmol) and the resulting mixture was stirred at room temperature under nitrogen for 1 hour. The reaction mixture was acidified to ca. pH 2 with a 5% aqueous potassium bisulfate solution, then partitioned  
15 between ethyl acetate and saturated sodium chloride solution. The aqueous layer was back extracted two times with ethyl acetate, and the combined organic layers were dried (sodium sulfate) and evaporated to yield 0.670 g of the title compound. TLC (methylene chloride-methanol-  
20 acetic acid, 32:1:1)  $R_f$ =0.35.  $^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ )  $\delta$

7.38-7.28 (m, 5H), 7.13-7.04 (m, 3H), 5.72 (d, J=8.1 Hz, 1H), 5.03 (s, 2H), 4.35 (m, 1H), 3.77-3.67 (m, 5H), 3.10 (m, 1H), 2.72-2.52 (m, 5H), 2.07 (m, 1H), 1.70 (m, 1H).

5


**PREPARATION 5****Preparation of N-(Benzyloxycarbonyl)-L-(N'-Methyl-N'-Methoxy)aspartamide  $\beta$ -(tert-Butyl Ester)**

10 To a solution of N-(benzyloxycarbonyl)-L-aspartic acid- $\beta$ -(tert-butyl)ester (14.65 g, 45.3 mmol, Bachem) in  $\text{CH}_2\text{Cl}_2$  (150 mL) at 0°C (ice bath) under a nitrogen atmosphere was added 1-hydroxybenzotriazole hydrate (7.29 g, 47.6 mmol, Aldrich) followed by 1-ethyl-  
15 3-(3',3'-dimethyl-1'-aminopropyl)carbodiimide hydrochloride (9.55 g, 49.8 mmol, Sigma). After stirring at 0°C for 15 min., N,O-dimethylhydroxylamine hydrochloride (5.10 g, 52.3 mmol, Aldrich) and N-methylmorpholine (5.8 mL, 53 mmol, Aldrich) were added.  
20 The mixture was allowed to warm to room temperature over 3 hours then stirred at room temperature for 16 hours. The solution was concentrated under vacuum and the residue partitioned between ethyl acetate-5%  $\text{KHSO}_4$  (200 mL each). The organic phase was washed in turn with 5%

KHSO<sub>4</sub>, saturated sodium bicarbonate and saturated sodium chloride solutions; dried over anhydrous sodium sulfate and evaporated to an oil. The oil was crystallized from hexane to give the title product (16.10 g, 97% yield) as  
5 a fluffy white crystalline solid. TLC (ethyl acetate), single spot (UV and PMA):  $R_f=0.37$ .

A similar procedure to the one above, starting with 29.3 g of N-(benzyloxycarbonyl)-L-aspartic acid- $\beta$ -(tert-butyl)ester (2-fold scale up) gave 31.18 g (94%  
10 yield) of the title product.

#### PREPARATION 6



#### **Preparation of N-(Benzyloxycarbonyl)-L-Aspartic Acid Semicarbazone $\beta$ -(tert-Butyl)Ester**

15 To a solution of N-(benzyloxycarbonyl)-L-(N'-methyl-N'-methoxy)aspartamide  $\beta$ -(tert-butyl ester) (15.50 g, 42.3 mmol) in anhydrous ether (400 mL) at 0°C (ice bath) under a nitrogen atmosphere was added dropwise to a 1.0 M solution of LiAlH<sub>4</sub> in ether (22.0 mL, 22.0 mmol,  
20 Aldrich) at such a rate as to keep the reaction solution temperature between 0-5°C (addition time 15-20 min).

After the addition of the lithium aluminum hydride reagent was complete, the mixture was stirred at 0-5°C for 1 hr, then quenched by the dropwise addition of 0.3 N KHSO<sub>4</sub> solution (100 mL). The resultant mixture was  
5 transferred to a separatory funnel adding sufficient 5% KHSO<sub>4</sub> solution (75 mL) to dissolve the solids. The organic phase was separated and the combined aqueous washes back-extracted with ether (100 mL). The combined ether extracts were washed with saturated NaCl solution,  
10 dried over anhydrous sodium sulfate and concentrated in vacuo with minimal heating. TLC (ethyl acetate): streaky spot (UV and PMA)  $R_f=0.48$ . TLC (methanol/methylene chloride, 1:9) major spot (UV and PMA):  $R_f=0.75$ .


15 The crude aldehyde was immediately taken up in aqueous ethanol (45 mL water/105 mL alcohol), placed in an ice bath and treated with sodium acetate (3.82 g, 46.6 mmol) and semicarbazide hydrochloride (5.20 g, 46.6 mmol, Aldrich). The mixture was stirred at 0°C (ice bath)  
20 under a nitrogen atmosphere for 3 hrs, allowed to warm to room temperature, and stirred overnight (16 hrs). Most of the ethanol was removed under vacuum and the residue partitioned between ethyl acetate and water (100 mL each). The organic phase was washed sequentially with 5%  
25 KHSO<sub>4</sub>, saturated sodium bicarbonate and saturated sodium chloride solutions; dried over anhydrous sodium sulfate and evaporated to dryness. The crude product of this reaction was combined with that of two similar procedures starting with 15.40 g and 4.625 g of N-  
30 (benzyloxycarbonyl)-L-(N'-methyl-N'-methoxy)aspartamide  $\beta$ -(tert-butyl ester) (total: 35.525 g, 97 mmol) and these combined products were purified by flash chromatography on silica gel eluting with acetone/methylene chloride (3:7) then methanol-acetone-



methylene chloride (0.5:3:7) to give pure title product (27.73 g, 78.5%) as a colorless foam. TLC (MeOH-CH<sub>2</sub>Cl<sub>2</sub>, 1:9): single spot (UV and PMA), R<sub>f</sub>=0.51.

#### PREPARATION 7

5



#### **Preparation of L-Aspartic Acid Semicarbazone β-(tert-Butyl) Ester, p-Toluenesulfonate Salt**

To a solution of N-(benzyloxycarbonyl)-L-aspartic acid semicarbazone β-(tert-butyl)ester (13.84 g, 38.0 mmol) in absolute ethanol (250 mL) was added 10% Pd/C (1.50 g, Aldrich) and the resulting mixture stirred under an atmosphere of hydrogen (balloon) until TLC (methanol/methylene chloride, 1:9) indicated complete consumption of the starting material (60 min). Note: It is important to follow this reaction closely since the product can be over-reduced. The mixture was filtered through Celite and evaporated to an oil. The oil was chased with methylene chloride (2 x 75mL) then with methylene chloride/toluene (1:1, 75 mL) to give the crude amine as a white crystalline solid. TLC (EtOAc-pyridine-AcOH-H<sub>2</sub>O; 60:20:5:10) single spot (UV and PMA) R<sub>f</sub>=0.24. Note: In this TLC system, any over-reduced product will

show up immediately below the desired product,  $R_f=0.18$  (PMA only).

The crude amine was taken up in  $\text{CH}_3\text{CN}$  (60 mL) and treated with a solution of p-toluenesulfonic acid monohydrate (7.22 g, 38.0 mmol) in acetonitrile (60 mL). The crystalline precipitate was collected, washed with acetonitrile and ether, and air-dried to give the title compound (13.95 g, 92% yield) as a white, crystalline solid.

The optical purity of this material was checked by conversion to the corresponding Mosher amide [1.05 equiv (R)-(-)- $\alpha$ -methoxy- $\alpha$ -(trifluoromethyl)phenylacetyl chloride, 2.1 equivalents of i- $\text{Pr}_2\text{NEt}$  in  $\text{CH}_2\text{Cl}_2$ , room temperature, 30 min]. The desired product has a doublet at 7.13 ppm (1H, d,  $J=2.4$  Hz,  $\text{CH}=\text{N}$ ) while the corresponding signal for its diastereomer is at 7.07 ppm. The optical purity of the title compound obtained from the above procedure is typically > 95:5.

#### PREPARATION 8

#### 20 **Assay for Inhibition of ICE/ced-3 Protease Family Activity**

##### A. Determination of $\text{IC}_{50}$ Values

Fluorescence enzyme assays detecting the activity of the compounds of Formula 1 utilizing the recombinant ICE and CPP32 enzymes were performed essentially according to Thornberry *et al.* (*Nature*, 356:768:774 (1992)) and Nicholson *et al.* (*Nature*, 376:37-43 (1995)) respectively, (herein incorporated by reference) in 96 well microtiter plates. The substrate

is Acetyl-Tyr-Val-Ala-Asp-amino-4-methylcoumarin (AMC) for the ICE assay and Acetyl-Asp-Glu-Val-Asp-amino-4-methylcoumarin for the CPP32, Mch2, Mch3 and Mch5 assays. Enzyme reactions were run in ICE buffer (25 mM HEPES, 1 mM EDTA, 0.1% CHAPS, 10% sucrose, pH 7.5) containing 2 mM DTT at room temperature in duplicate. The assays were performed by mixing the following components:

- 50  $\mu$ L ICE, Mch2, Mch5, CPP32 (18.8, 38, 8.1 and 0.153 nM concentrations, respectively) or Mch3 (1 unit) enzyme in ICE buffer containing either 8.0 (ICE, Mch2, Mch3, CPP32) or 20 (Mch5) mM DTT;
- 50  $\mu$ L compound of Formula 1 or ICE buffer (control); and
- 100  $\mu$ L of 20  $\mu$ M substrate.

The enzyme and the compound of Formula 1 to be assayed were allowed to preincubate in the microtitre plate wells for 30 minutes at room temperature prior to the addition of substrate to initiate the reaction. Fluorescent AMC product formation was monitored for one hour at room temperature by measuring the fluorescence emission at 460 nm using an excitation wavelength of 360 nm. The fluorescence change in duplicate (control) wells were averaged and the mean values were plotted as a function of inhibitor concentration to determine the inhibitor concentration producing 50% inhibition ( $IC_{50}$ ). The results of this assay are set forth below in Table 1.

The reference compound for this assay was Cbz-ValAlaAsp-H and the values are denoted in Table 1 as "Reference".

TABLE 1

Example No.	mICE IC <sub>50</sub> (μM)	CPP32 IC <sub>50</sub> (μM)	MCH-2 IC <sub>50</sub> (μM)	MCH-3 IC <sub>50</sub> (μM)	MCH-5 IC <sub>50</sub> (μM)
3	0.019	1.03	40.1	6.96	>10
7	0.694	0.0014	6.47	0.145	2.09
10	0.571	0.245	1.81	2.83	7.98
13	0.096	0.00052	ND	0.084	1.19
16	0.045	0.780	>10	32.6	18.7
19	3.07	3.87	>10	>50	>50
25	0.159	8.77	>50	>50	4.63
22	0.010	2.91	>50	12.3	1.09
28	0.026	0.437	32.0	1.11	2.06
Ref.	0.064	47.0	>10	>10	2.96

### B. Determination of the dissociation constant

K<sub>i</sub> and irreversible rate constant k<sub>3</sub> for irreversible inhibitors

For the irreversible inhibition of a ICE/ced-3 Family Protease enzyme with a competitive irreversible inhibitor; using the model represented by the following formulas:



The product formation at time t may be expressed as:

$$[P]_t = [E]^T \left( \frac{[S]K_i}{[I]K_s} \right) \left( \frac{k_s}{k_3} \right) \left[ 1 - e^{-k_3 t / (1 + \frac{K_i}{[I]} (1 + \frac{[S]}{K_s}))} \right]$$


Equation 1

where E, I, EI and E-I denote the active enzyme, inhibitor, non-covalent enzyme-inhibitor complex and covalent enzyme-inhibitor adduct, respectively. The  $K_i$  value is the overall dissociation constant of the reversible binding steps, and  $k_3$  is the irreversible rate constant. The  $[S]$  and  $K_s$  values are the substrate concentration and dissociation constant of the substrate bound to the enzyme, respectively.  $[E]^T$  is the total enzyme concentration.

The above equations were used to determine the  $K_i$  and  $k_3$  values of a given inhibitor bound to a ICE/ced-3 family protease. Thus, a continuous assay was run for sixty minutes at various concentrations of the inhibitor and the substrate. The assay was formulated essentially the same as described above for generating the data in Table 1, except that the reaction was initiated by adding the enzyme to the substrate-inhibitor mixture. The  $K_i$  and  $k_3$  values were obtained by simulating the product AMC formation as a function of time according to Equation 1. The results of this second assay are set forth below in Table 2.

The reference compound for this assay was Cbz-ValAlaAsp-CH<sub>2</sub>F and the values are denoted in Table 2 as "Reference".


TABLE 2				
	Example 31		Reference	
Enzyme	Ki ( $\mu$ M)	k <sub>3</sub> /Ki ( $\mu$ M)	Ki ( $\mu$ M)	k <sub>3</sub> /Ki (M <sup>-1</sup> s <sup>-1</sup> )
mICE	0.0005	12,000,000	0.015	214,000
CPP32	0.012	960,000	0.820	12,200
MCH-2	0.033	25,000	0.594	2,950
MCH-5	0.022	98,000	0.018	83,300

**EXAMPLE 1**

10 (2S-cis)-[5-Benzyloxycarbonylamino-1,2,4,5,6,7-Hexahydro-4-Oxoazepino[3,2,1-hi]indole-2-Carbonyl) amino]-4-Oxobutanoic Acid tert-Butyl Ester Semicarbazone

To a solution of (2S-cis)-5-benzyloxycarbonylamino-1,2,4,5,6,7-hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carboxylic acid (0.375 g, 0.989 mmol) in methylene chloride (7 mL) stirring at 0°C under nitrogen was added 1-hydroxybenzotriazole hydrate (0.182 g, 1.19 mmol) and 1-ethyl-3-(3',3'-dimethyl-1'-aminopropyl)carbodiimide hydrochloride (0.284 g, 1.48

- mmol). After 15 minutes L-aspartic acid semicarbazone  $\beta$ -(tert-butyl) ester, p-toluenesulfonate salt (0.386 g, 0.989 mmol) and N-methylmorpholine (0.163 mL, 1.48 mmol) were added and the resultant reaction mixture allowed to
- 5 come to room temperature within 1 hour. After stirring overnight, the reaction mixture was diluted with ethyl acetate and washed successively with 5% potassium bisulfate and saturated sodium chloride solutions; dried over sodium sulfate and evaporated to dryness.
- 10 Purification of the crude product by flash chromatography on silica gel (S/P brand silica gel 60Å, 230-400 mesh ASTM) eluting with 2% methanol-methylene chloride gave 0.463 g (79%) of the title compound as a white foam. TLC (methylene chloride-methanol, 9:1):  $R_f$ =0.5.  $^1\text{H-NMR}$  (300
- 15 MHz,  $\text{CDCl}_3$ ):  $\delta$  8.42 (s, 1H), 7.82 (d,  $J$ =8.1 Hz, 1H), 7.32 (m, 5H), 7.07 (m, 3H), 5.94 (d,  $J$ =6.3 Hz, 1H), 5.26 (d,  $J$ =9 Hz, 1H), 5.10 (s, 2H), 4.82 (m, 1H), 4.35 (m, 1H), 3.56 (d,  $J$ =18 Hz, 1H), 3.27 (m, 2H), 3.07 (m, 1H), 2.64 (dd,  $J$ =4.7, 15.8 Hz, 1H), 2.44 (dd,  $J$ =6.6, 15.9 Hz, 2H),
- 20 2.22 (m, 1H), 1.30 (s, 9H). Mass spectrum:  $m/z$  593 (M+H).


**EXAMPLE 2**

**(2-cis)-[5-Benzyloxycarbonylamino-1,2,4,5,6,7-hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carbonyl)-amino]-4-oxo-butanoic acid semicarbazone**

To a solution of (2S-cis)-[5-benzyloxycarbonylamino-1,2,4,5,6,7-hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carbonyl)amino]-4-oxo-butanoic acid tert-butyl ester semicarbazone (0.214 g, 0.362 mmol) in methylene chloride (1.5 mL) was added anisole (0.5 mL, 4.34 mmol) followed by trifluoroacetic acid (0.75 mL). After stirring at room temperature under nitrogen for 2 hours the reaction mixture was diluted with methylene chloride and evaporated, then chased twice with methylene chloride to give the title compound (0.195 g). TLC (methylene chloride-methanol, 95:5),  $R_f$ =0.2.  $^1\text{H}$ -NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  9.77 (bs, 1H), 8.32 (d,  $J$ =12 Hz, 1H), 8.12 (d,  $J$ =7.8 Hz, 1H), 7.31-7.27 (m, 5H) 7.13-7.04 (m, 3H), 6.64 (m, 1H) 5.32 (d,  $J$ =9.9 Hz, 1H), 5.12 (s,




2H), 4.86 (m, 1H), 4.41 (m, 1H), 3.56 (d, J=15 Hz, 1H), 3.25 (m, 2H), 3.10 (m, 2H), 2.64 (m, 2H), 2.28 (m, 2H).

**EXAMPLE 3**

5 (2S-cis)-5-[Benzyloxycarbonylamino-1,2,4,5,6,7-hexahydro-4-oxazepino[3,2,1-hi]indole-2-carbonyl)-amino]-4-oxobutanoic acid


(2-cis)-[5-Benzyloxycarbonylamino-1,2,4,5,6,7-hexahydro-4-oxazepino[3,2,1-hi]indole-2-carbonyl)-amino]-4-oxobutanoic acid semicarbazone (0.195 g, 0.36 mmol) was treated with a 3:1:1 solution of methanol-acetic acid-37% formaldehyde (2 mL) and the resulting mixture stirred under nitrogen for 1.5 hours. The reaction mixture was diluted with water, methanol removed by evaporation, then the remaining mixture lyophilized. Purification of the crude product by flash chromatography on revers phase gel (MCI gel, CHP-20P, 75-150

micron) eluting with a 10%-80% methanol-water gradient gave 0.073 g, (42%) of the title compound as a white solid after lyophilization; m.p. 101-104°C. TLC (methylene chloride-methanol-acetic acid, 97:2.5:0.5)  $R_f=0.45$ .  $^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ )  $\delta$  7.45 (m, 1H), 7.30 (s, 5H), 7.07 (d,  $J=3.3$  Hz, 1H), 7.00 (d,  $J=4.8$  Hz, 2H), 6.12 (m, 1H), 5.17 (d,  $J=9.6$  Hz, 1H), 5.07 (s, 2H), 4.49 (m, 1H), 4.28 (m, 1H), 3.46 (d,  $J=9.9$  Hz, 1H), 3.30-3.12 (m, 2H), 3.04-2.99 (m, 1H), 2.83-2.76 (m, 1H), 2.46-2.33 (m, 2H), 2.03 (bs, 1H). Mass spectrum:  $m/z$  480 ( $M+H$ ).

**EXAMPLE 4**

(2S-cis)-[5-Amino-1,2,3,4,5,6,7-hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carbonyl)-amino]-4-oxo-butanoic acid tert-butyl ester semicarbazone


10% Palladium on carbon (0.180 g) was added to a solution of (2S-cis)-[5-benzyloxycarbonylamino-1,2,3,4,5,6,7-hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carbonyl)-amino]-4-oxo-butanoic acid tert-butyl ester  
5 semicarbazone (0.308 g, 0.520 mmol) in methanol (27 mL) and the resulting mixture was hydrogenated using a balloon of hydrogen (1 atm, R.T.) for 18 hours. The mixture was filtered through Celite, evaporated to dryness, then chased two times with toluene to give the  
10 title compound as an off-white solid (0.215 g). TLC (methylene chloride-methanol, 9:1)  $R_f=0.15$ .  $^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ )  $\delta$  8.53 (s, 1H), 7.89 (d,  $J=7.6$  Hz, 1H), 7.13 (m, 3H), 5.21 (dd,  $J=2.3, 10.14$  Hz, 1H), 4.82 (m, 1H), 3.52 (m, 1H), 3.24 (dd,  $J=10.3, 16.3$  Hz, 1H), 3.03 (m,  
15 2H), 2.62 & 2.42 (AB, dd,  $J=4.2, 7.1, 15.7$  Hz, 2H), 2.19 (m, 1H), 1.32 (s, 9H).

**EXAMPLE 5**

(2S-cis)-[5-(N-Acetyl-(S)-aspartyl- $\beta$ -tert-butyl ester)amino-1,2,3,4,5,6,7-hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carbonyl)-amino]-4-oxo-butanoic acid tert-butyl ester semicarbazone


To a solution of N-acetyl aspartic acid,  $\beta$ -tert-butyl ester (0.120 g, 0.517 mmol) in methylene chloride (1.5 mL) stirring at 0°C under nitrogen was added 1-hydroxybenzotriazole hydrate (0.086 g, 0.564 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.135 g, 0.705 mmol). After 15 minutes, a solution of (2S-cis)-[5-amino-1,2,3,4,5,6,7-hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carbonyl)-amino]-4-oxo-butanoic acid tert-butyl ester semicarbazone (0.213 g, 0.47 mmol) in methylene chloride (2 mL) was added and the reaction was allowed to come to room temperature over 1

hour. After stirring overnight, the reaction mixture was diluted with ethyl acetate and washed successively with 5% potassium bisulfate and saturated sodium chloride solutions; dried (sodium sulfate) and evaporated to dryness. Purification of the crude product by flash chromatography on silica gel (S/P brand silica gel 60Å, 230-400 mesh ASTM) eluting with 5% then 10% methanol-methylene chloride gave 0.126 g (41%) of the title compound as a white solid. TLC (methylene chloride-methanol, 9:1)  $R_f$ =0.4.  $^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ )  $\delta$  9.63 (s, 1H), 8.32 (d,  $J$ =7.8 Hz, 1H), 7.82 (d,  $J$ =6.6 Hz, 1H), 7.53 (d,  $J$ =4.8 Hz, 1H), 7.09 (m, 1H), 7.00 (m, 2H), 5.18 (d,  $J$ =8.1 Hz, 1H), 4.86 (m, 1H), 4.39 (m, 1H), 3.01 (m, 1H), 2.92 (dd,  $J$ =4.2, 14.7 Hz, 1H) 2.68 (d,  $J$ =12.3 Hz, 1H), 2.52 (m, 2H), 2.51 (m, 2H), 2.03 (s, 3H), 1.39 (s, 9H), 1.24 (s, 9H).

EXAMPLE 6

(2S-cis)-[5-(N-Acetyl-(S)-aspartyl)amino-1,2,3,4,5,6,7-hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carbonyl)-  
 5 amino]-4-oxo-butanoic acid semicarbazone


To a solution of (2S-cis)-[5-(N-acetyl-(S)-aspartyl- $\beta$ -tert-butyl ester)amino-1,2,3,4,5,6,7-hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carbonyl)-amino]-4-oxo-butanoic acid tert-butyl ester semicarbazone  
 10 (0.117 g, 0.178 mmol) in methylene chloride (1 mL) was added anisole (0.5 mL) followed by trifluoroacetic acid (1 mL). After stirring at room temperature under nitrogen for 2 hours, the reaction mixture was diluted with methylene chloride and evaporated, then chased twice  
 15 with methylene chloride to give the title compound (0.099 g). TLC (methylene chloride-methanol-acetic acid, 13:6:1)  $R_f$ =0.2. Mass spectrum:  $m/z$  560 (M+H).

EXAMPLE 7

(2S-cis)-[5-(N-Acetyl-(S)-aspartyl)amino-1,2,3,4,5,6,7-hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carbonyl)-  
5 amino]-4-oxo-butanoic acid

(2S-cis)-[5-(N-Acetyl-(S)-aspartyl)amino-1,2,3,4,5,6,7-hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carbonyl)-amino]-4-oxo-butanoic acid semicarbazone (0.097 g, 0.177 mmol), was treated with a 3:1:1 solution of  
10 methanol-acetic acid-37% formaldehyde (2 mL) and the resulting mixture stirred under nitrogen for 1.5 hours. The reaction mixture was then diluted with water, methanol removed by evaporation, then the remaining mixture lyophilized. Purification of the crude product  
15 by flash chromatography on reverse phase gel (MCI gel, CHP-20P, 75-150 micron) eluting with a 10%-80% methanol-water gradient gave 0.050g (56%) of the title compound as a white solid after lyophilization; m.p. 160-175°C (dec).

TLC (methylene chloride-methanol-acetic acid, 13:6:1)  
 $R_f=0.3$ . Mass spectrum:  $m/z$  503 (M+H).

**EXAMPLE 8**


5 (2S-cis)-[5-Succinylamino-1,2,3,4,5,6,7-hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carbonyl)-amino]-4-oxo-butanoic acid tert-butyl ester semicarbazone

To a solution of (2S-cis)-[5-amino-1,2,3,4,5,6,7-hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carbonyl)-amino]-4-oxo-butanoic acid tert-butyl ester semicarbazone (0.197 g, 0.435 mmol) in methylene chloride (6 mL) stirring at 0°C under nitrogen was added succinic anhydride (0.057 g, 0.566 mmol), followed by pyridine (0.052 mL, 0.653 mmol). After stirring at room temperature under nitrogen for 3 hours, the reaction mixture was diluted with ethyl acetate and washed successively with 5% potassium bisulfate and saturated



sodium chloride solutions; dried (sodium sulfate) and evaporated to dryness. Purification of the crude product by flash chromatography on silica gel (S/P brand silica gel 60Å, 230-400 mesh ASTM) eluting with 10% methanol-  
 5 methylene chloride then 80:19:1 methylene chloride-methanol-acetic acid gave 0.216 g (88%) of the title compound as a white solid. TLC (methylene chloride-methanol-acetic acid, 8:1:1)  $R_f$ =0.5. Mass spectrum:  $m/z$  557 (M-H).

10

**EXAMPLE 9**


**(2S-cis)-[5-Succinylamino-1,2,3,4,5,6,7-hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carbonyl)-amino]-4-oxo-butanoic acid semicarbazone**

15

To a solution of (2S-cis)-[5-succinylamino-1,2,3,4,5,6,7-hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carbonyl)-amino]-4-oxo-butanoic acid tert-butyl ester

semicarbazone (0.191g, 0.342 mmol) in methylene chloride (1 mL) was added anisole (0.5 mL) followed by trifluoroacetic acid (1 mL). After stirring at room temperature under nitrogen for 2 hours, the reaction mixture was diluted with methylene chloride and evaporated, then chased twice with methylene chloride to give the title compound (0.210 g). TLC (methylene chloride-methanol-acetic acid, 8:1:1)  $R_f$ =0.4. Mass spectrum:  $m/z$  503 (M+H).

10


EXAMPLE 10

(2S-cis)-[5-Succinylamino-1,2,3,4,5,6,7-hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carbonyl)-amino]-4-oxobutanoic acid

15

(2S-cis)-[5-Succinylamino-1,2,3,4,5,6,7-hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carbonyl)-amino]-4-oxobutanoic acid semicarbazone (0.208 g, ca. 0.342 mmol), was treated with a 3:1:1 solution of


methanol-acetic acid-37% formaldehyde (3 mL), and the resulting mixture stirred under nitrogen for 1.5 hours. The reaction mixture was then diluted with water, methanol removed by evaporation, then the remaining  
5 mixture lyophilized. Purification of the crude product by flash chromatography on reverse phase gel (MCI gel, CHP-20P, 75-150 micron) eluting with a 10%-80% methanol-water gradient gave 0.064 g (42%) of the title compound as a white solid after lyophilization; m.p. 145-160°C  
10 (dec). TLC (methylene chloride-methanol-acetic acid, 8:1:1)  $R_f$ =0.45. Mass spectrum:  $m/z$  446 (M+H).

**EXAMPLE 11**

(2S-cis)-[5-(N-Benzyloxycarbonyl-(S)-aspartyl- $\beta$ -tert-butyl ester)amino-1,2,3,4,5,6,7-hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carbonyl)-amino]-4-oxo-butanoic acid tert-butyl ester semicarbazone


To a solution of N-benzyloxycarbonyl-(S)-aspartyl- $\beta$ -tert-butyl ester (0.169 g, 0.521 mmol) in methylene chloride (1.5 mL) stirring at 0°C under nitrogen was added 1-hydroxybenzotriazole hydrate (0.087 g, 0.569 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.136 g, 0.711 mmol). After 15 minutes, a solution of (2S-cis)-[5-amino-1,2,3,4,5,6,7-hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carbonyl)-amino]-4-oxo-butanoic acid tert-butyl ester semicarbazone (0.217 g, 0.474 mmol) in methylene chloride (2 mL) was added and the reaction was allowed to come to

room temperature within 1 hour. After stirring overnight, the reaction mixture was diluted with ethyl acetate and washed successively with 5% potassium bisulfate and saturated sodium chloride solutions; dried (sodium sulfate) and evaporated to dryness. Purification of the crude product by flash chromatography on silica gel (S/P brand silica gel 60Å, 230-400 mesh ASTM) eluting with 2% then 5% methanol-methylene chloride gave 0.244 g (67%) of the title compound as an off-white solid. TLC (methylene chloride-methanol, 9:1)  $R_f=0.55$ .  $^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ )  $\delta$  9.13 (s, 1H), 7.85 (d,  $J=6$  Hz, 1H), 7.56 (d,  $J=5.7$  Hz, 1H) 7.23 (m, 5H), 7.08 (m, 1H), 7.00 (m, 2H), 5.13 (m, 3H) 4.77 (m, 1H), 4.62 (m, 1H), 4.43 (m, 1H), 3.60 (d,  $J=16$  Hz, 1H), 3.22 (m, 2H), 2.98 (m, 1H), 2.83 (d,  $J=15.3$  Hz, 1H), 2.65 & 2.36 (AB, dd,  $J=4.2, 7.7, 16.9$  Hz, 2H), 2.42 (m, 1H), 2.10 (m, 1H), 1.35 (s, 9H), 1.24 (s, 9H).

**EXAMPLE 12**

(2S-cis)-[5-(N-Benzyloxycarbonyl-(S)-aspartyl)amino-  
1,2,3,4,5,6,7-hexahydro-4-oxoazepino[3,2,1-hi]indole-2-  
5 carbonyl)-amino]-4-oxo-butanoic acid semicarbazone


To a solution of (2S-cis)-[5-(N-Benzyloxycarbonyl-(S)-aspartyl- $\beta$ -tert-butyl ester)amino-1,2,3,4,5,6,7-hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carbonyl)-amino]-4-oxo-butanoic acid tert-butyl ester  
10 semicarbazone (0.217 g, 0.289 mmol) in methylene chloride (1 mL) was added anisole (0.5 mL) followed by trifluoroacetic acid (1 mL). After stirring at room temperature under nitrogen for 3 hours, the reaction mixture was diluted with methylene chloride and  
15 evaporated, then chased twice with methylene chloride to give the title compound (0.193 g). TLC (methylene chloride-methanol, 9:1)  $R_f$ =0.35. Mass spectrum:  $m/z$  652 (M+H).

**EXAMPLE 13**

(2S-cis)-[5-(N-Benzyloxycarbonyl-(S)-aspartyl)amino-1,2,3,4,5,6,7-hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carbonyl)-amino]-4-oxo-butanoic acid

(2S-cis)-[5-(N-Benzyloxycarbonyl-(S)-aspartyl)amino-1,2,3,4,5,6,7-hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carbonyl)-amino]-4-oxo-butanoic acid semicarbazone (0.191 g, 0.29 mmol), was treated with a 3:1:1 solution of methanol-acetic acid-37% formaldehyde (2 mL) and the resulting mixture stirred under nitrogen for 2 hours. The reaction mixture was then diluted with water, methanol removed by evaporation, then the remaining mixture lyophilized. Purification of the crude product by flash chromatography on reverse phase gel (MCI gel, CHP-20P, 75-150 micron) eluting with a 10%-80% methanol-water gradient gave 0.111 g. (64%) of the title compound as a white solid after lyophilization;

m.p. 140-144°C (dec.). TLC (methylene chloride-methanol, 9:1)  $R_f$ =0.4. Mass spectrum:  $m/z$  593 (M-H).


**EXAMPLE 14**

- 5    **(2S-cis)-[5-Dihydrocinnamylamino-1,2,3,4,5,6,7-hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carbonyl)-amino]-4-oxobutanoic acid tert-butyl ester semicarbazone**

To a solution of dihydrocinnamic acid (0.169 g, 0.521 mmol) in methylene chloride (1.5 mL) stirring at 10 0°C under nitrogen was added 1-hydroxybenzotriazole hydrate (0.088 g, 0.576 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.127 g, 0.665 mmol). After 15 minutes, a solution of (2S-cis)-[5-amino-1,2,3,4,5,6,7-hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carbonyl)-amino]-4-oxobutanoic acid tert-butyl ester semicarbazone (0.203 g, 0.443 mmol) in methylene chloride (2 mL), was added and 15 the reaction was allowed to come to room temperature




within 1 hour. After stirring overnight, the reaction mixture was diluted with ethyl acetate and washed successively with 5% potassium bisulfate and saturated sodium chloride solutions; dried (sodium sulfate) and  
5 evaporated to dryness. Purification of the crude product by flash chromatography on silica gel (S/P brand silica gel 60Å, 230-400 mesh ASTM) eluting with 2 then 5% methanol-methylene chloride gave 0.208 g (79%) of the title compound as an off-white solid. TLC (methylene  
10 chloride-methanol, 9:1)  $R_f=0.7$ .  $^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ )  $\delta$  8.82 (s, 1H), 7.72 (d,  $J=8.1$  Hz, 1H), 7.19 (m, 5H), 7.06 (m, 1H), 7.01 (m, 2H), 6.76 (d,  $J=6.3$ , 1H), 5.23 (d,  $J=8.4$  Hz, 1H), 4.84 (m, 1H), 4.50 (m, 1H), 3.48 (m, 1H), 3.26 (m, 2H), 3.05 (m, 1H), 2.94 (m, 2H), 2.53 (m, 4H),  
15 2.28 (m, 1H), 2.06 (m, 1H), 1.29 (s, 9H). Mass spectrum:  $m/z$  591 (M+H).

**EXAMPLE 15**

(2S-cis)-[5-Dihydrocinnamylamino-1,2,3,4,5,6,7-hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carbonyl)-amino]-4-oxo-butanoic acid semicarbazone


To a solution of (2S-cis)-[5-dihydrocinnamylamino-1,2,3,4,5,6,7-hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carbonyl)-amino]-4-oxo-butanoic acid tert-butyl ester semicarbazone (0.189 g, 0.320 mmol) in methylene chloride (1 mL) was added anisole (0.5 mL) followed by trifluoroacetic acid (1 mL). After stirring at room temperature under nitrogen for 3 hours, the reaction mixture was diluted with methylene chloride and evaporated, then chased twice with methylene chloride to give the title compound (0.183 g). TLC(methylene chloride-methanol, 9:1)  $R_f$ =0.25. Mass spectrum:  $m/z$  535 (M+H).

EXAMPLE 16

(2S-cis)-[5-Dihydrocinnamylamino-1,2,3,4,5,6,7-hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carbonyl)-amino]-4-oxo-  
5 butanoic acid

(2S-cis)-[5-Dihydrocinnamylamino-1,2,3,4,5,6,7-hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carbonyl)-amino]-4-oxo-butanoic acid semicarbazone (0.181 g, ca. 0.320 mmol), was treated with a 3:1:1 solution of  
10 methanol-acetic acid-37% formaldehyde (2 mL) and the resulting mixture stirred under nitrogen for 4 hours. The reaction mixture was then diluted with water, methanol removed by evaporation, then the remaining mixture lyophilized. Purification of the crude product  
15 by flash chromatography on reverse phase gel (MCI gel, CHP-20P, 75-150 micron) eluting with a 10%-80% methanol-water gradient gave 0.075 g (47%) of the title compound as a white solid after lyophilization; m.p. 78-81°C. TLC (methylene chloride-methanol, 9:1)  $R_f$ =0.45.  $^1\text{H-NMR}$  (300


MHz, DMSO d<sub>6</sub>)  $\delta$  8.58 (m, 1H), 8.30 (d, J= 7.5 Hz, 1H), 7.24 (m, 5H), 7.08 (m, 2H), 6.99 (m, 1H), 5.04 (d, J=9.3 Hz, 1H), 4.39 (m, 1H), 4.19 (m, 1H), 3.46 (m, 1H), 3.05 (m, 2H), 2.93 (d, J= 16.8 Hz, 2H), 2.83 (m, 2H), 2.00 (d, J= 5.1 Hz, 2H). Mass spectrum: m/z 478 (M+H).

**EXAMPLE 17**

(2S-cis)-[5-Acetylamino-1,2,3,4,5,6,7-hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carbonyl)-amino]-4-oxo-butanoic acid tert-butyl ester semicarbazone


To a solution of (2S-cis)-[5-amino-1,2,3,4,5,6,7-hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carbonyl)-amino]-4-oxo-butanoic acid tert-butyl ester semicarbazone (0.222 g, 0.490 mmol) in pyridine (3 mL) at room temperature under nitrogen was added acetic anhydride (0.07 mL, 0.735 mmol). After stirring overnight, the reaction mixture was diluted with

methylene chloride and evaporated to give a foam. This was taken up in ethyl acetate and washed successively with 5% potassium bisulfate and saturated sodium chloride solutions; dried (sodium sulfate) and evaporated to dryness to give 0.130 g (53%) of the title compound as an off-white solid. TLC (methylene chloride-methanol, 9:1)  $R_f=0.55$ .  $^1\text{H}$ - NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  8.75 (s, 1H), 7.75 (d,  $J=8.4$  Hz, 1H), 7.08 (m, 1H), 7.01 (m, 2H), 6.87 (d,  $J=6.3$  Hz, 1H), 5.25 (d,  $J=8.1$  Hz, 1H), 4.84 (m, 1H), 4.52 (m, 1H), 3.50 (m, 1H), 3.28 (m, 2H), 3.02 (m, 1H), 2.55 & 2.46 (AB, dd,  $J=4.2, 7.1, 15.7$  Hz, 2H), 2.36 (m, 1H), 2.18 (m, 1H), 2.02 (s, 3H), 1.31 (s, 9H).

EXAMPLE 18

(2S-cis)-[5-Acetylamino-1,2,3,4,5,6,7-hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carbonyl)-amino]-4-oxo-butanoic acid semicarbazone


To a solution of (2S-cis)-[5-acetylamino-1,2,3,4,5,6,7-hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carbonyl)-amino]-4-oxo-butanoic acid tert-butyl ester semicarbazone (0.112 g, 0.224 mmol) in methylene chloride  
10 (1 mL) was added anisole (0.5 mL) followed by trifluoroacetic acid (1 mL). After stirring at room temperature under nitrogen for 2.5 hours, the reaction mixture was diluted with methylene chloride and evaporated, then chased twice with methylene chloride to  
15 give the title compound (0.117 g). TLC (methylene chloride-methanol, 9:1)  $R_f=0.15$ . Mass spectrum:  $m/z$  445 (M+H).

EXAMPLE 19

(2S-cis)-[5-Acetylamino-1,2,3,4,5,6,7-hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carbonyl)-amino]-4-oxo-butanoic acid

(2S-cis)-[5-Acetylamino-1,2,3,4,5,6,7-hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carbonyl)-amino]-4-oxo-butanoic acid semicarbazone (0.115 g, ca. 0.224 mmol) was treated with a 3:1:1 solution of methanol-acetic acid-37% formaldehyde (2 mL) and the resulting mixture stirred under nitrogen for 5 hours. The reaction mixture was diluted with water, methanol removed by evaporation, then the remaining mixture lyophilized. Purification of the crude product by flash chromatography on reverse phase gel (MCI gel, CHP-20P, 75-150 micron) eluting with a 10%-80% methanol-water gradient gave 0.044 g (51%) of the title compound as a white solid after lyophilization; m.p. 210-215°C (dec).

TLC (methylene chloride-methanol-acetic acid, 44:5:1)  
 $R_f=0.45$ . Mass spectrum:  $m/z$  388 (M+H).


**EXAMPLE 20**

- 5 (2S-cis)-[5-(1-Naphthoyl)amino-1,2,3,4,5,6,7-hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carbonyl)-amino]-4-oxobutanoic acid tert-butyl ester semicarbazone

To a solution of 1-naphthoic acid (0.072 g, 0.417 mmol) in methylene chloride (1.5 mL) stirring at  
 10 0°C under nitrogen was added 1-hydroxybenzotriazole hydrate (0.077 g, 0.501 mmol.) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.120 g, 0.626 mmol). After 15 minutes, a solution of  
 15 (2S-cis)-[5-amino-1,2,3,4,5,6,7-hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carbonyl)-amino]-4-oxo-




butanoic acid tert-butyl ester semicarbazone (0.189 g, 0.147 mmol) in methylene chloride (2 mL), was added and the reaction was allowed to come to room temperature within 1 hour. After stirring a total of 5 hours, the  
5 reaction mixture was diluted with ethyl acetate and washed successively with 5% potassium bisulfate and saturated sodium chloride solutions, dried (sodium sulfate) and evaporated to dryness. Purification of the crude product by flash chromatography on silica gel (S/P  
10 brand silica gel 60Å, 230-400 mesh ASTM) eluting with 5% methanol-methylene chloride gave 0.168 g (66%) of the title compound as an off-white solid; m.p. 103-105°C (dec.). TLC (methylene chloride-methanol, 9:1)  $R_f$ =0.6. Mass spectrum:  $m/z$  613 (M+H).  $^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ )  $\delta$   
15 9.09 (bs, 1H), 8.38 (d,  $J=8.4$  Hz, 1H), 7.82-7.93 (m, 3H), 7.70 (d,  $J=6.3$  Hz, 1H), 7.45-7.58 (m, 3H), 7.37 (d,  $J=6.6$  Hz, 1H), 7.06-7.15 (m, 4H), 5.30 (d,  $J=8.4$  Hz, 1H), 4.80-4.85 (m, 2H), 3.57 (d,  $J=3.6$  Hz, 1H), 3.30-3.45 (m, 2H), 3.16 (m, 1H), 2.59-2.65 (m, 2H), 2.27-2.49 (m, 2H),  
20 1.29 (s, 9H).

**EXAMPLE 21**

(2S-cis)-[5-(1-Naphthoyl)amino-1,2,3,4,5,6,7-hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carbonyl)-amino]-4-oxo-butanoic acid semicarbazone

To a solution of (2S-cis)-[5-(1-naphthoyl)amino-1,2,3,4,5,6,7-hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carbonyl)-amino]-4-oxo-butanoic acid tert-butyl ester semicarbazone (0.106 g, 0.173 mmol) in methylene chloride (1 mL) was added anisole (0.5 mL) followed by trifluoroacetic acid (1 mL). After stirring at room temperature under nitrogen for 3 hours, the reaction mixture was diluted with methylene chloride and evaporated, then chased twice with methylene chloride to give the title compound (0.110 g). TLC (methylene chloride-methanol, 9:1)  $R_f$ =0.3.


**EXAMPLE 22**

(2S-cis)-[5-(1-Naphthoyl)amino-1,2,3,4,5,6,7-hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carbonyl)-amino]-4-oxo-  
 5 butanoic acid

(2S-cis)-[5-(1-Naphthoyl)amino-1,2,3,4,5,6,7-hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carbonyl)-amino]-4-oxo-butanoic acid semicarbazone (0.110 g, ca. 0.173 mmol) was treated with a 3:1:1 solution of  
 10 methanol-acetic acid-37% formaldehyde (3 mL) and the resulting mixture stirred under nitrogen for 5 hours. The reaction mixture was then diluted with water, methanol removed by evaporation, then the remaining mixture lyophilized. Purification of the crude product  
 15 by flash chromatography on silica gel (S/P brand silica gel 60Å, 230-400 mesh ASTM) eluting with a 5%-20%

methanol-methylene chloride gradient gave 0.076g (86%) of the title compound as a white solid; m.p. 202-203°C (dec). TLC(methylene chloride-methanol-acetic acid, 20:1:1)  $R_f$ =0.3. Mass spectrum:  $m/z$  498 (M-H).  $^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ )  $\delta$  9.38 (bs, 1H), 8.94 (m, 1H), 8.56 (m, 1H), 8.36 (m, 1H), 7.94-8.02 (m, 2H), 7.68 (d,  $J=6.9$  Hz, 1H), 7.51-7.59 (m, 3H), 7.07-7.13 (m, 2H), 6.97 (m, 1H), 5.20 (d,  $J=10.5$ , 1Hz), 4.67 (m, 1H), 4.15 (m, 1H), 3.49 (m, 1H), 2.95-3.23 (m, 2H), 2.53 (m, 1H), 2.22-2.34 (m, 2H).

10

**EXAMPLE 23**


**(2S-cis)-[5-Benzoylamino-1,2,3,4,5,6,7-hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carbonyl)-amino]-4-oxo-butanoic acid tert-butyl ester semicarbazone**

15

To a solution of (2S-cis)-[5-amino-1,2,3,4,5,6,7-hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carbonyl)-amino]-4-oxo-butanoic acid tert-butyl ester


semicarbazone (0.121 g, 0.264 mmol) in methylene chloride (2.5 mL) stirring at 0°C under nitrogen was added triethylamine (0.055 mL, 0.396 mmol), followed by benzoyl chloride (0.037 mL, 0.317 mmol). After stirring at room temperature under nitrogen for 1 hour, the reaction mixture was diluted with ethyl acetate and washed successively with 5% potassium bisulfate, saturated sodium bicarbonate and saturated sodium chloride solutions; dried (sodium sulfate) and evaporated to dryness. Purification of the crude product by flash chromatography on silica gel (S/P brand silica gel 60Å, 230-400 mesh ASTM) eluting with 10% hexane-ethyl acetate, 100% ethyl acetate, then 10% methanol-ethyl acetate gave 0.073 g (49%) of the title compound as a off-white solid.

TLC (methylene chloride-methanol, 9:1)  $R_f$ =0.7. Mass spectrum:  $m/z$  563 (M+H).  $^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ )  $\delta$  8.61 (bs, 1H), 7.83-7.86 (m, 2H), 7.47-7.53 (m, 3H), 7.06-7.12 (m, 3H), 5.30 (dd,  $J$ = 2.2, 7.8 Hz, 1H), 4.89 (m, 1H), 4.72 (m, 1H), 3.60 (d,  $J$ = 16.5 Hz, 1H), 3.36 (m, H), 3.19 (m, 1H), 2.69 (dd,  $J$ = 4.4, 11.7 Hz, 1H), 2.52 (m, 1H), 2.29 (m, 1H), 1.34 (s, 9H).

**EXAMPLE 24**

(2S-cis)-[5-Benzoylamino-1,2,3,4,5,6,7-hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carbonyl)-amino]-4-oxo-butanoic acid semicarbazone


To a solution of (2S-cis)-[5-benzoylamino-1,2,3,4,5,6,7-hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carbonyl)-amino]-4-oxo-butanoic acid tert-butyl ester semicarbazone (0.064 g, 0.114 mmol) in methylene chloride (1 mL) was added anisole (0.5 mL) followed by trifluoroacetic acid (1 mL). After stirring at room temperature under nitrogen for 2.5 hours, the reaction mixture was diluted with ethyl acetate and evaporated to give the title compound (0.070 g). TLC (methylene chloride-methanol, 4:1)  $R_f=0.4$ . Mass spectrum:  $m/z$  507 (M+H).

EXAMPLE 25

(2S-cis)-[5-Benzoylamino-1,2,3,4,5,6,7-hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carbonyl)-amino]-4-oxo-butanoic acid

(2S-cis)-[5-Benzoylamino-1,2,3,4,5,6,7-hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carbonyl)-amino]-4-oxo-butanoic acid semicarbazone (0.070 g, ca. 0.114 mmol) was treated with a 3:1:1 solution of  
10 methanol-acetic acid-37% formaldehyde (3 mL), and the resulting mixture stirred under nitrogen for 3.5 hours. The reaction mixture was then diluted with water, methanol removed by evaporation, then the remaining mixture lyophilized. Purification of the crude product  
15 by flash chromatography on silica gel (S/P brand silica gel 60Å, 230-400 mesh ASTM) eluting with 10 and 20% methanol-methylene chloride gave 0.042 g (82%) of the title compound as a white solid; m.p. 204-205°C (dec). TLC (methylene chloride-methanol, 4:1)  $R_f$ =0.4. Mass

spectrum: m/z 448 (M-H). <sup>1</sup>H-NMR (300 MHz, DMSO-d<sub>6</sub>) δ 8.84 (m, 1H), 8.53 (m, 1H), 7.91-7.95 (m, 2H), 7.46-7.58 (m, 3H), 7.11 (m, 2H), 6.99 (t, J=7.3 Hz, 1H), 5.14 (d, 10.2 Hz, 1H), 4.62 (m, 1H), 4.23 (m, 1H), 3.48 (m, 1H), 3.12-3.18 (m, 2H), 2.99 (m, 1H), 2.58 (m, 1H), 2.12-2.46 (m, 3H).


**EXAMPLE 26**

(3R,S-cis)-6-Benzyloxycarbonylamino-5-oxo-2,3,4,5,6,7,8-hexahydro-1H-azepino[3,2,1-hi]quinoline-3-carbonyl)-amino]-4-oxo-butanoic acid tert-butyl ester semicarbazone

To a solution of (3R,S-cis)-6-benzyloxycarbonylamino-5-oxo-2,3,4,5,6,7,8-hexahydro-1H-azepino[3,2,1-hi]quinoline-3-carboxylic acid (0.604 g, 1.5 mmol) in methylene chloride (12 mL) stirring at 0°C under nitrogen was added 1-hydroxybenzotriazole hydrate (0.282 g, 1.8 mmol) and 1-(3-dimethylaminopropyl)-3-




ethylcarbodiimide hydrochloride (0.442 g, 3 mmol). After 15 minutes, L-aspartic acid semicarbazone  $\beta$ -tert-butyl ester, p-toluenesulfonate salt (0.60 g, 1.5 mmol) and N-methylmorpholine (0.25 mL, 3 mmol) were added and the mixture allowed to come to room temperature within 1 hour. After stirring an additional hour, the reaction mixture was diluted with ethyl acetate and washed successively with 5% potassium bisulfate and saturated sodium chloride solutions; dried (sodium sulfate) and evaporated to dryness. Purification of the crude product by flash chromatography on silica gel (S/P brand silica gel 60Å, 230-400 mesh ASTM) eluting with 10% methanol-methylene chloride gave 0.523 g (56%) of the title compound as a white foam. TLC (methylene chloride-methanol, 9:1)  $R_f$ =0.65.  $^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ )  $\delta$  9.89 (m, 1H), 7.72 (m, 1H), 7.92 (d,  $J$ =9 Hz, 1H), 7.65 (d,  $J$ =8.1 Hz, 1H), 7.32-7.28 (m, 5H), 7.12 (s, 1H), 7.07 (d,  $J$ =5.7 Hz, 2H), 6.03 (d,  $J$ =7.5 Hz, 1H), 5.84 (d,  $J$ =8.1 Hz, 1H), 5.03 (s, 2H), 5.01 (m, 1H) 4.80 (m, 1H), 4.31 (m, 1H), 2.98 (m, 1H), 2.75-2.41 (m, 7H), 2.12 (m, 1H), 1.77 (m, 1H), 1.39 (s, 9H).

**EXAMPLE 27**

(3R,S-cis)-6-Benzyloxycarbonylamino-5-oxo-2,3,4,5,6,7,8-hexahydro-1H-azepino[3,2,1-hi]quinoline-3-carbonyl)-  
5 amino]-4-oxo-butanoic acid semicarbazone


To a solution of (3R,S-cis)-6-Benzyloxycarbonylamino-5-oxo-2,3,4,5,6,7,8-hexahydro-1H-azepino[3,2,1-hi]quinoline-3-carbonyl)-amino]-4-oxo-butanoic acid tert-butyl ester semicarbazone (0.200 g,  
10 0.33 mmol) in methylene chloride (1 mL) was added anisole (0.5 mL, 4.62 mmol) followed by trifluoroacetic acid (1 mL). After stirring at room temperature under nitrogen for 1.5 hours the reaction mixture was diluted with methylene chloride and evaporated, then azeotroped twice  
15 with methylene chloride to give the title compound (0.248 g). TLC (methylene chloride-methanol-acetic acid, 8:1:1)  $R_f$ =0.2. Mass spectrum:  $m/z$  549  $[M-H]^+$ .

**EXAMPLE 28**

(3R,S-cis)-6-Benzyloxycarbonylamino-5-oxo-2,3,4,5,6,7,8-hexahydro-1H-azepino[3,2,1-hi]quinoline-3-carbonyl)-5-amino]-4-oxo-butanoic acid

(3R,S-cis)-6-Benzyloxycarbonylamino-5-oxo-2,3,4,5,6,7,8-hexahydro-1H-azepino[3,2,1-hi]quinoline-3-carbonyl)-amino]-4-oxo-butanoic acid semicarbazone (0.245 g, ca 0.33 mmol), was treated with a 3:1:1 solution of methanol-acetic acid-37% formaldehyde (3 mL) and the resulting mixture stirred under nitrogen for 1.5 hours. The reaction mixture was diluted with water, methanol removed by evaporation, then the remaining mixture lyophilized. Purification of the crude product by flash chromatography on reverse phase gel (MCI gel, CHP-20P, 75-150 micron) eluting with a 10%-80% methanol-water gradient gave 0.090 g (60%) of the title compound as a white solid after lyophilization; m.p. 120-123°C (dec). TLC (methylene chloride-methanol-acetic acid, 32:1:1)


$R_f=0.45$ .  $^1\text{H-NMR}$  (300 MHz, DMSO  $d_6$ )  $\delta$  8.67 (m, 1H), 7.79 (m, 1H), 7.57 (m, 1H), 7.37-7.27 (m, 5H), 7.17-7.08 (m, 3H), 5.44 (m, 1H), 4.95 (s, 2H), 4.70 (m, 1H), 4.07 (m, 1H), 3.92 (m, 1H), 3.16 (m, 1H), 2.98 (m, 1H), 2.75-2.41 (m, 7H), 2.25 (m, 1H), 2.11 (m, 1H), 1.29 (m, 1H). Mass spectrum:  $m/z$  492  $[\text{M-H}]^-$ .

**EXAMPLE 29**

10 3-((2S-cis)-[5-Benzyloxycarbonylamino-1,2,3,4,5,6,7-hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carbonyl)-amino]-5-fluoro-4-hydroxy-pentanoic acid tert-butyl ester

To a solution of (2S-cis)-5-benzyloxycarbonylamino-1,2,3,4,5,6,7-hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carboxylic acid (0.373 g, 0.98 mmol) in methylene chloride (3 mL) stirring at 0°C under nitrogen was added 1-hydroxybenzotriazole hydrate (0.151 g, 0.98 mmol) and 1-(3-dimethylaminopropyl)-3-

ethylcarbodiimide hydrochloride (0.283 g, 1.47 mmol). After 15 minutes, 3-amino-4-hydroxy-5-fluoropentanoic acid, tert-butyl ester (0.204 g, 0.98 mmol, prepared as described in Tetrahedron Letters 35, pp. 9693-9696 (1994)) was added and the mixture allowed to come to room temperature within 1 hour. After stirring overnight, the reaction mixture was diluted with ethyl acetate and washed successively with 5% potassium bisulfate and saturated sodium chloride solutions; dried (sodium sulfate) and evaporated to dryness. Purification of the crude product by flash chromatography on silica gel (S/P brand silica gel 60Å, 230-400 mesh ASTM) eluting with 2% methanol-methylene chloride gave 0.383 g (68%) of the title compound as a white foam. TLC (methylene chloride-methanol, 9:1)  $R_f=0.6$ .  $^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ )  $\delta$  7.45-7.31 (m, 5H), 7.08-7.01 (m, 3H), 6.10 (m, 1H), 5.26 (m, 1H), 5.12 (s, 2H), 4.52 (m, 1H), 4.38-4.30 (m, 2H), 4.21-4.19 (m, 2H), 4.03-3.95 (m, 2H), 3.43-3.20 (m, 4H), 3.13 (m, 2H), 2.62-2.50 (m, 2H), 2.42 (m, 1H), 1.42 (s, 4H), 1.32 (s, 5H). Mass spectrum:  $m/z$  570 (M+H).


**EXAMPLE 30**

3{ (2S-cis)- [5-Benzyloxycarbonylamino-1,2,3,4,5,6,7-  
 hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carbonyl)-  
 5 amino]}-5-fluoro-4-oxo-pentanoic acid tert-butyl ester

To a solution of 3{ (2S-cis)-[5-benzyloxycarbonylamino-1,2,3,4,5,6,7-hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carbonyl)-amino]}-5-fluoro-4-hydroxy-pentanoic acid tert-butyl ester (0.114 g, 0.20  
 10 mmol) in methyl sulfoxide (1.3 mL) was added Dess-Martin periodinane (0.228 g). After stirring at room temperature under nitrogen for 2 hours an additional portion of Dess-Martin periodinane (0.135 g) was added followed 2.5 hours later by a third portion (0.10 g).  
 15 The reaction mixture was diluted with ethyl acetate and washed twice with water and saturated sodium chloride solution; dried (sodium sulfate) and evaporated to dryness. Purification of the crude product by flash chromatography on silica gel (S/P brand silica gel 60Å,  
 20 230-400 mesh ASTM) eluting 1/1 ethyl acetate-hexanes gave

0.076 g (67%) of the title compound as a white foam. TLC (ethyl acetate-hexanes, 1:1)  $R_f=0.6$ .  $^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ )  $\delta$  7.58 (d,  $J = 8.4$  Hz, 1H), 7.34-7.30 (m, 5H), 7.07-6.99 (m, 3H), 6.06 (m, 1H), 5.23 (d,  $J = 12.3$  Hz, 1H), 5.12 (s, 2H), 4.53 (d,  $J = 13.2$  Hz, 1H), 4.77 (d,  $J = 9.9$  Hz, 2H), 4.32 (m, 1H), 3.44 (dd,  $J = 5, 8.4$  Hz, 1H), 3.32-3.21 (m, 2H), 3.06 (m, 1H), 2.9 (m, 1H), 2.62 (m, 1H), 2.41 (m, 1H), 2.17 (m, 1H), 1.39 (s, 4H), 1.29 (s, 5H).

10

**EXAMPLE 31**


**3((2S-cis)- [5-Benzyloxycarbonylamino-1,2,3,4,5,6,7-hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carbonyl)-amino))-5-fluoro-4-oxo-pentanoic acid**

15

To a solution of 3((2S-cis)-[5-benzyloxycarbonylamino-1,2,3,4,5,6,7-hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carbonyl)-amino))-5-fluoro-4-oxo-pentanoic acid tert-butyl ester (0.063 g, 0.111 mmol) in methylene chloride (1.0 mL) was added anisole

(0.5 mL), followed by trifluoroacetic acid (1.0 mL). After stirring at room temperature under nitrogen for 2 hours the reaction mixture was diluted with methylene chloride and evaporated, then chased twice with methylene chloride. The crude residue was triturated with ethyl ether to give 0.030 g of the titled product as a white solid; m.p. 106-107°C (dec). TLC (methylene chloride-methanol-acetic acid, 32:1:1)  $R_f$ =0.3.  $^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ )  $\delta$  7.61 (m, 1H), 7.32 (s, 5H), 7.1 (d,  $J$  = 4 Hz, 1H), 7.03 (d,  $J$  = 4 Hz, 2H), 6.17 (m, 1H), 5.22 (m, 1H), 5.10 (s, 2H), 4.75-4.70 (m, 2H), 4.32 (m, 1H), 3.5 (m, 1H), 3.31-3.15 (m, 2H), 3.03 (m, 1H), 2.93 (m, 1H), 2.69 (m, 1H), 2.36 (m, 1H), 2.12 (m, 1H). Mass spectrum:  $m/z$  512 (M+H).



**EXAMPLE 32**

3-[(2S-cis)-[5-Benzyloxycarbonylamino-1,2,3,4,5,6,7-  
hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carbonyl]amino]-  
5-bromo-4-oxo-pentanoic acid, tert-butyl ester\_


To a solution of (2S-cis)-5-benzyloxycarbonylamino-1,2,3,4,5,6,7-hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carboxylic acid (0.302 g, 0.797 mmol) in methylene chloride (5.5 mL) stirring at 0°C under nitrogen was added 1-hydroxybenzotriazole hydrate (0.146 g, 0.96 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.230 g, 1.2 mmol). After 15 minutes, aspartic acid, α-methyl, β-tert-butyl diester hydrochloride (0.191 g, 0.797 mmol) was added followed by N-methylmorpholine (0.13 mL, 1.2 mmol) and the mixture allowed to come to room temperature within 1 hour. After stirring overnight, the reaction mixture was diluted with ethyl acetate and washed successively with 5% potassium

bisulfate and saturated sodium chloride solutions; dried (sodium sulfate) and evaporated to dryness. Purification of the crude product by flash chromatography on silica gel (S/P brand silica gel 60Å, 230-400 mesh ASTM) eluting  
5 with ethyl acetate-hexane (1:1) gave 0.350 g (78%) of N-[(2S-cis)-[5-benzyloxy- carbonylamino-1,2,3,4,5,6,7-hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carbonyl]]aspartic acid,  $\alpha$ -methyl,  $\beta$ -tert-butyl diester as a white solid. TLC (methylene chloride-methanol, 9:1 )  
10  $R_f$  = 0.8. m.p. 147-148°C(dec.).  $^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.48 (d,  $J=7.5$  Hz, 1H), 7.34-7.29 (m, 5H), 7.07 (m, 1H), 7.03-6.96 (m, 2H), 6.15 (d,  $J=5.7$  Hz, 1H), 5.28 (d,  $J=7.8$  Hz 1H), 5.11 (s, 2H), 4.72 (m, 1H), 4.32 (m, 1H), 3.74 (s, 3H), 3.49 (d,  $J=16.5$  Hz, 1H), 3.31-3.20 (m, 2H),  
15 3.05 (m, 1H), 2.72 (ABX, dd,  $J=4.65$ , 15, 64.5 Hz, 2H), 2.43 (m, 1H), 2.15 (m, 1H), 1.30 (s, 9H).

To a solution of the above product (0.330 g, 0.585 mmol) in 1,4-dioxane (4.5 mL) and water (1.5 mL) was added 1M aqueous lithium hydroxide (0.7 mL, 0.702  
20 mmol) and the resulting mixture was stirred at room temperature under nitrogen for 30 minutes. The reaction mixture was acidified to pH 3 with a 0.1N HCl solution, then partitioned between ethyl acetate and saturated sodium chloride solution. The aqueous layer was back  
25 extracted two times with ethyl acetate, and the combined organic layers were dried (sodium sulfate) and evaporated to yield 0.275 g (85%) of N-[(2S-cis)-[5-benzyloxy carbonylamino-1,2,3,4,5,6,7-hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carbonyl]]aspartic acid,  $\beta$ -  
30 tert-butyl ester as a white foam. TLC(methylene chloride-methanol, 9:1):  $R_f$  = 0.25.  $^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.57 (d,  $J=7.8$  Hz, 1H), d7.35-7.29 (m, 5H), 7.08 (m, 1H), 7.03-6.98 (m, 2H), 6.24 (d,  $J=6$  Hz, 1H), 5.28 (d,  $J=5.1$  Hz 1H), 5.11 (s, 2H), 4.73 (m, 1H), 4.35 (m, 1H),

3.48 (d,  $J=16.8$  Hz, 1H), 3.36-3.20 (m, 2H), 3.07 (m, 1H), 2.76 (ABX, dd,  $J=4.8$ , 18, 66 Hz, 2H), 2.40 (m, 1H), 2.19 (m, 1H), 1.33 (s, 9H).


5 To a solution of the above product (0.262 g, 0.475 mmol) in tetrahydrofuran (3.0 mL) stirring at  $-10^{\circ}\text{C}$  under nitrogen was added N-methylmorpholine (0.114 mL, 1.05 mmol) followed by dropwise addition of isobutyl chloroformate (0.107 mL, 0.81 mmol). After 40 minutes  
10 the reaction mixture was filtered, the salts washed with dry THF, and the filtrate cooled to  $0^{\circ}\text{C}$ . This was treated with a freshly prepared ethereal solution of diazomethane (excess). After stirring the mixture at  $0^{\circ}\text{C}$  for 30 minutes, a mixture of hydrobromic acid (48% wt.  
15 aq. solution)/acetic acid (1.3 mL, 1/1) was added dropwise. After stirring for another 10 minutes, the reaction mixture was diluted with ethyl acetate, then washed successively with saturated sodium bicarbonate and saturated sodium chloride solutions; dried (sodium  
20 sulfate) and evaporated to dryness. Purification of the crude product by flash chromatography on silica gel (S/P brand silica gel 60Å, 230-400 mesh ASTM) eluting with ethyl acetate-hexane (1:1) gave 0.200 g (67%) of the title compound as a white foam. TLC(ethyl acetate-hexane,  
25 1:1 ):  $R_f = 0.7$ .  $^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.71 (d,  $J=9$  Hz, 1H), 7.35-7.30 (m, 5H), 7.09 (m, 1H), 7.04-7.02 (m, 2H), 6.1 (d,  $J=5.4$  Hz, 1H), 5.28 (d,  $J=7.2$  Hz 1H), 5.12 (s, 2H), 4.89 (dd,  $J=4.5$ , 15 Hz 1H), 4.35 (m, 1H), 4.16 (s, 2H), 3.50-3.21(m, 3H), 3.06 (m, 1H), 2.76 (ABX, dd,  
30  $J=4.65$ , 18, 103 Hz, 2H), 2.37 (m, 1H), 2.15 (m, 1H), 1.27 (s, 9H). Mass spectrum:  $m/z$  626/628 (M-H).

**EXAMPLE 33**

3-[(2S-cis)-[5-Benzyloxycarbonylamino-1,2,3,4,5,6,7-  
 hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carbonyl]amino]-  
 5 5-(diphenylphosphinyloxy)-4-oxo-pentanoic acid, tert-  
 butyl ester

To a solution of 3-[(2S-cis)-[5-  
 benzyloxycarbonylamino -1,2,3,4,5,6,7-hexahydro-4-  
 10 oxoazepino[3,2,1-hi]indole-2-carbonyl]amino]-5-bromo-4-  
 oxo-pentanoic acid, tert-butyl ester (0.069 g, 0.110  
 mmol) in N,N-dimethylformamide (1.0 mL) was added  
 potassium fluoride (0.029 g, 0.495 mmol), followed  
 diphenylphosphinic acid (0.029 g, 0.139 mmol). After  
 15 stirring at room temperature under nitrogen for 48 hours,  
 the reaction mixture was diluted with ethyl acetate, then  
 washed successively with a dilute sodium bicarbonate  
 solution then water; dried (sodium sulfate) and  
 evaporated to dryness. Purification of the crude product  
 20 by flash chromatography on silica gel (S/P brand silica  
 gel 60Å, 230-400 mesh ASTM) eluting with ethyl acetate-  
 hexane (1:1) gave 0.048 g (59%) of the title compound as

a clear oil. TLC(ethyl acetate-hexane, 2:1 ):  $R_f$  =0.3.  $^1\text{H}$ -NMR(300 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.89-7.80 (m, 4H), 7.52-7.30 (m, 11H), 7.06 (m, 1H), 7.01-6.96 (m, 2H), 6.45 (m, 1H), 5.21 (m, 1H), 5.13 (s, 2H), 4.96 (dd,  $J$ =8.3, 18 Hz, 1H), 4.78-4.70 (m, 2H), 4.35 (m, 1H), 3.35-3.23 (m, 3H), 3.05 (m, 1H), 2.76 (ABX, dd,  $J$ =4.65, 18, 103 Hz, 2H), 2.43 (m, 1H), 2.18 (m, 1H), 1.33 (s, 9H).

**EXAMPLE 34**

10 3-[(2S-cis)-[5-Benzyloxycarbonylamino-1,2,3,4,5,6,7-hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carbonyl]amino]-5-(diphenylphosphinyloxy)-4-oxopentanoic acid


To a solution of 3-[(2S-cis)-[5-benzyloxycarbonylamino-1,2,3,4,5,6,7-hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carbonyl]amino]-5-(diphenylphosphinyloxy)-4-oxopentanoic acid, tert-butyl ester (0.040 g, 0.054 mmol) in methylene chloride (1.0 mL) was added anisole (0.5 mL), followed by trifluoroacetic acid (1.0 mL). After stirring at room temperature under nitrogen for 30 minutes the reaction

mixture was diluted with methylene chloride and evaporated, then azeotroped twice with methylene chloride. The crude residue was triturated with ethyl ether to give 0.030 g of the titled product as a white solid; m.p. 109-111°C(dec). TLC(methylene chloride-methanol, 9:1):  $R_f$  = 0.4.  $^1\text{H-NMR}$ (300 Mhz,  $\text{CDCl}_3$ ):  $\delta$  7.87-7.66 (m, 4H), 7.60-7.28 (m, 11H), 7.05-6.95 (m, 3H), 6.84 (m, 1H), 5.12(s, 2H), 5.05 (m, 1H), 4.58 (m, 1H), 4.42-4.15 (m, 4H), 3.35-3.10 (m, 4H), 3.05 (m, 1H), 2.76 (m, 1H), 2.56 (m, 1H), 2.37(m, 1H), 2.13 (m, 1H), 1.93 (bs, 1H). Mass spectrum: m/z 710 (M+H).

101

We Claim:

1. A compound of the formula:



wherein:

5


n is 1 or 2;

m is 1 or 2;

A is  $R^2CO-$ ,  $R^3-O-CO-$ , or  $R^4SO_2-$ ;

a group of the formula:

10



further wherein:

R<sup>1</sup> is a hydrogen atom, alkyl or phenylalkyl;

5 R<sup>2</sup> is alkyl, cycloalkyl, (cycloalkyl)alkyl, phenyl, phenylalkyl, substituted phenyl, (substituted phenyl)alkyl, heteroaryl, or (heteroaryl)alkyl;

10 R<sup>3</sup> is alkyl, cycloalkyl, (cycloalkyl)alkyl, phenylalkyl, or (substituted phenyl)alkyl;

R<sup>4</sup> is alkyl, cycloalkyl, (cycloalkyl)alkyl, phenyl, phenylalkyl, substituted phenyl, (substituted phenyl)alkyl, heteroaryl, or (heteroaryl)alkyl;

15 R<sup>5</sup> is alkyl, cycloalkyl, (cycloalkyl)alkyl, phenyl, phenylalkyl, substituted phenyl, (substituted phenyl)alkyl, heteroaryl, or (heteroaryl)alkyl;

20 R<sup>6</sup> is alkyl, cycloalkyl, (cycloalkyl)alkyl, phenylalkyl, or (substituted phenyl)alkyl;

R<sup>7</sup> is alkyl, cycloalkyl, (cycloalkyl)alkyl, phenyl, phenylalkyl, substituted phenyl, (substituted phenyl)alkyl, heteroaryl, or (heteroaryl)alkyl;


25 R<sup>8</sup> is an amino acid side chain chosen from the group consisting of natural and unnatural amino acids;



5

B is a hydrogen atom, a deuterium atom, alkyl, cycloalkyl, (cycloalkyl)alkyl, phenyl, phenylalkyl, substituted phenyl, (substituted phenyl)alkyl, heteroaryl, (heteroaryl)alkyl, or halomethyl;


a group of the formula:



10


wherein  $\text{R}^9$  is phenyl, substituted phenyl, phenylalkyl, (substituted phenyl)alkyl, heteroaryl, or (heteroaryl)alkyl; and X is an oxygen or a sulfur atom;

a group of the formula:




a group of the formula:

15



a group of the formula:




20

wherein  $\text{R}^{10}$  and  $\text{R}^{11}$  are independently selected from a group consisting of alkyl, cycloalkyl, phenyl, substituted phenyl, phenylalkyl, and (substituted phenyl)alkyl;

or a pharmaceutically-acceptable salt thereof.

2. A compound of claim 1, wherein n is 1.
3. A compound of claim 2, wherein m is 1.
4. A compound of claim 3, wherein B is a hydrogen atom.
- 5 5. A compound of claim 4, wherein A is a group of the formula  $R^2CO-$ .
6. A compound of claim 5, wherein  $R^2$  is a group of the formula 2-(carboxy)eth-1-yl, 2-(phenyl)eth-1-yl, methyl, naphth-1-yl, or phenyl.
- 10 7. A compound of claim 6, wherein  $R^1$  is a hydrogen atom.
8. A compound of claim 4, wherein A is a group of the formula:  
$$R^5-CO-NH-CHR^6-CO-;$$
- 15 wherein  $R^5$  is methyl and  $R^6$  is a group of the formula  $-CH_2COOH$ .
9. A compound of claim 8, wherein  $R^1$  is a hydrogen atom.
10. A compound of claim 4, wherein A is a  
20 group of the formula  $R^3-O-CO-$ , and wherein  $R^3$  is benzyl.
11. A compound of claim 10, wherein  $R^1$  is a hydrogen atom.

12. A compound of claim 4, wherein A is a group of the formula:



wherein  $R^6$  is benzyl and  $R^8$  is a group of the formula -  
5  $CH_2COOH$ .


13. A compound of claim 12, wherein  $R^1$  is a hydrogen atom.

14. A compound of claim 3, wherein B is a group of the formula  $-CH_2F$ .

10 15. A compound of claim 14, wherein A is a group of the formula  $R^3-O-CO-$ , wherein  $R^3$  is benzyl.

16. A compound of claim 15, wherein  $R^1$  is a hydrogen atom.

15 17. A compound of claim 3, wherein B is a group of the formula;




18. A compound of claim 17, wherein  $R^{10}$  and  $R^{11}$  are each phenyl.

19. A compound of claim 18, wherein A is a  
20 group of the formula  $R^3-O-CO-$ , and wherein  $R^3$  is a benzyl group.

20. A compound of claim 19, wherein  $R^1$  is a hydrogen atom.

21. A compound of claim 1, wherein n is 2.
22. A compound of claim 21, wherein m is 1.
23. A compound of claim 22, wherein B is a hydrogen atom.
- 5 24. A compound of claim 23, wherein A is a group of the formula  $R^3-O-CO-$ , and  $R^3$  is a benzyl group.
25. A compound of claim 24, wherein  $R^1$  is a hydrogen atom.
26. A pharmaceutical composition comprising a  
10 compound of the formula:



wherein:


n is 1 or 2;

m is 1 or 2;

5

A is  $R^2CO-$ ,  $R^3-O-CO-$ , or  $R^4SO_2-$ ;

a group of the formula:



further wherein:

10

$R^1$  is a hydrogen atom, alkyl or phenylalkyl;

$R^2$  is alkyl, cycloalkyl, (cycloalkyl)alkyl, phenyl, phenylalkyl, substituted phenyl, (substituted phenyl)alkyl, heteroaryl, or (heteroaryl)alkyl;

15

$R^3$  is alkyl, cycloalkyl, (cycloalkyl)alkyl, phenylalkyl, or (substituted phenyl)alkyl;

20

$R^4$  is alkyl, cycloalkyl, (cycloalkyl)alkyl, phenyl, phenylalkyl, substituted phenyl, (substituted phenyl)alkyl, heteroaryl, or (heteroaryl)alkyl;

R<sup>5</sup> is alkyl, cycloalkyl, (cycloalkyl)alkyl, phenyl, phenylalkyl, substituted phenyl, (substituted phenyl)alkyl, heteroaryl, or (heteroaryl)alkyl;

5 R<sup>6</sup> is alkyl, cycloalkyl, (cycloalkyl)alkyl, phenylalkyl, or (substituted phenyl)alkyl;

10 R<sup>7</sup> is alkyl, cycloalkyl, (cycloalkyl)alkyl, phenyl, phenylalkyl, substituted phenyl, (substituted phenyl)alkyl, heteroaryl, or (heteroaryl)alkyl;

R<sup>8</sup> is an amino acid side chain chosen from the group consisting of natural and unnatural amino acids;

15 B is a hydrogen atom, a deuterium atom, alkyl, cycloalkyl, (cycloalkyl)alkyl, phenyl, phenylalkyl, substituted phenyl, (substituted phenyl)alkyl, heteroaryl, (heteroaryl)alkyl, or halomethyl;

a group of the formula

20  $-\text{CH}_2\text{XR}^9$ ;

wherein R<sup>9</sup> is phenyl, substituted phenyl, phenylalkyl, (substituted phenyl)alkyl, heteroaryl, and (heteroaryl)alkyl; and X is an oxygen or a sulfur atom;

25 a group of the formula

-CH<sub>2</sub>-O-CO-(aryl);

or a group of the formula

-CH<sub>2</sub>-O-CO-(heteroaryl);

a group of the formula:

5 -CH<sub>2</sub>-O-PO-(R<sup>10</sup>) R<sup>11</sup>;

wherein R<sup>10</sup> and R<sup>11</sup> are independently selected from a group consisting of alkyl, cycloalkyl, phenyl, substituted phenyl, phenylalkyl, and (substituted phenyl)alkyl;

10 and a pharmaceutically-acceptable carrier thereof.

27. A pharmaceutical composition of claim 26, wherein n is 1.

28. A pharmaceutical composition of claim 27,  
15 wherein m is 1.

29. A compound pharmaceutical composition of claim 28, wherein B is a hydrogen atom.


30. A pharmaceutical composition of claim 29, wherein A is a group of the formula R<sup>2</sup>CO.

20 31. A pharmaceutical composition of claim 30, wherein R<sup>2</sup> is a group of the formula 2-(carboxy)eth-1-yl, 2-(phenyl)eth-1-yl, methyl, naph-1-yl, or phenyl.

32. A pharmaceutical composition of claim 31 wherein R<sup>1</sup> is a hydrogen atom.

33. A pharmaceutical composition of claim 29, wherein A is a group of the formula:

5




wherein R<sup>5</sup> is methyl and R<sup>8</sup> is a group of the formula -CH<sub>2</sub>COOH.

34. A compound of claim 33, wherein R<sup>1</sup> is a hydrogen atom.

10

35. A compound of claim 29, wherein A is a group of the formula:



wherein R<sup>6</sup> is benzyl and R<sup>8</sup> is a group of the formula -CH<sub>2</sub>COOH.

15

36. A compound of claim 35, wherein R<sup>1</sup> is a hydrogen atom.

37. A compound of claim 28, wherein B is a group of the formula -CH<sub>2</sub>F.


38. A compound of claim 37, wherein A is a group of the formula R<sup>3</sup>-O-CO-, wherein R<sup>3</sup> is benzyl.

20

39. A compound of claim 38, wherein R<sup>1</sup> is a hydrogen atom.



40. A compound of claim 28, wherein B is a group of the formula;



41. A compound of claim 40, wherein  $\text{R}^{10}$  and  $\text{R}^{11}$  are each phenyl.

42. A compound of claim 41, wherein A is a group of the formula  $\text{R}^3-\text{O}-\text{CO}-$ , and wherein  $\text{R}^3$  is a benzyl group.

43. A compound of claim 42, wherein  $\text{R}^1$  is a hydrogen atom.

44. A compound of claim 26, wherein n is 2.

45. A compound of claim 44, wherein m is 1.

46. A compound of claim 28, wherein B is a hydrogen atom.

47. A compound of claim 46, wherein A is a group of the formula  $\text{R}^3-\text{O}-\text{CO}-$ , and  $\text{R}^3$  is a benzyl group.

48. A compound of claim 47, wherein  $\text{R}^1$  is a hydrogen atom.

49. A method for treating an autoimmune disease comprising administering an effective amount of a pharmaceutical composition of claim 26 to a patient in need of such treatment.

50. A method of treating an inflammatory disease comprising administering an effective amount of

the pharmaceutical composition of claim 26 to a patient in need of such treatment.

51. A method of treating a neurodegenerative disease comprising administering an effective amount of the pharmaceutical composition of claim 26 to a patient in need of such treatment.

52. A method of preventing ischemic injury to a patient suffering from a disease associated with ischemic injury comprising administering an effective amount of the pharmaceutical composition of claim 26 to a patient in need of such treatment.

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 97/16156

## A. CLASSIFICATION OF SUBJECT MATTER

IPC6: C07D 487/04, C07D 471/04, C07F 9/32, C07K 14/81, A61K 31/47, A61K 31/40, A61K 31/66

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: C07D, C07F, C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CA, WPI

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Tetrahedron Letters, Volume 35, No 41, 1994, Stéphane De Lombaert et al, "Practical Syntheses of a Novel Tricyclic Dipeptide Mimetic Based on a (6H)-Azepino Indoline Nucleus: Application to Angiotensin-Converting Enzyme Inhibition" page 7513 - page 7516	1-52
X	WO 9501353 A1 (CIBA-GEIGY AG), 12 January 1995 (12.01.95)	1-52
X	EP 0595610 A1 (E.R. SQUIBB & SONS, INC.), 4 May 1994 (04.05.94)	1-52

☒ Further documents are listed in the continuation of Box C. ☒ See patent family annex.

### \* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "B" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

17 December 1997

Date of mailing of the international search report

06.01.98

Name and mailing address of the ISA/



European Patent Office, P.B. 5818 Patentlaan 2  
NL-2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 cpo nl.  
Fax: (+31-70) 340-3016

Authorized officer

GERD STRANDELL

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International application No.

PCT/US 97/16156

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9501353 A1	12/01/95	AU 7186094 A	24/01/95
		EP 0706525 A	17/04/96
		JP 9500113 T	07/01/97
		US 5644055 A	01/07/97
-----			
EP 0595610 A1	04/05/94	AT 152721 T	15/05/97
		AU 661616 B	27/07/95
		AU 5027393 A	12/05/94
		CA 2107443 A	29/04/94
		DE 69310475 D,T	04/09/97
		ES 2101960 T	16/07/97
		JP 7300479 A	14/11/95
US 5504080 A	02/04/96		
-----			

# INTERNATIONAL SEARCH REPORT

national application No.

PCT/US 97/16156

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

- 1 ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely  
Remark: Although claim(s) 49-52  
is(are) directed to a method of treatment of the human/animal  
body, the search has been carried out and based on the alleged  
effects of the compound/composition.
- 2 ☐ Claims Nos.  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such  
an extent that no meaningful International Search can be carried out, specifically
- 3 ☐ Claims Nos.  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6 4(a)

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows.

- 1 ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all  
searchable claims
- 2 ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee
- 3 ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report  
covers only those claims for which fees were paid, specifically claims Nos.
- 4 ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is  
restricted to the invention first mentioned in the claims; it is covered by claims Nos.

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest
- ☐ No protest accompanied the payment of additional search fees

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 97/16156

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>J. Med. Chem., Volume 36, 1993, Gary A. Flynn et al,  "Application of a Conformationally Restricted  Phe-Leu Dipeptide Mimetic to the Design of a  Combined Inhibitor of Angiotensin I-Converting  Enzyme and Neutral Endopeptidase 24.11"  page 2420 - page 2423</p> <p style="text-align: center;">--  -----</p>	1-52